



the 23 and Me Research Team, eQTLGen Consortium, & BIOS Consortium (2019). Genetic Architectures of Childhood- and Adult-Onset Asthma Are Partly Distinct. *American Journal of Human Genetics*, 104(4), 665-684. <https://doi.org/10.1016/j.ajhg.2019.02.022>

Peer reviewed version

License (if available):
CC BY-NC-ND

Link to published version (if available):
[10.1016/j.ajhg.2019.02.022](https://doi.org/10.1016/j.ajhg.2019.02.022)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at <https://doi.org/10.1016/j.ajhg.2019.02.022> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Genetic architectures of childhood- and adult-onset asthma are partly distinct

Manuel AR Ferreira¹, Riddhima Mathur¹, Judith M Vonk², Agnieszka Sz wajda³, Ben Brumpton^{4,5,6},
Raquel Granell⁷, Bronwyn K Brew³, Vilhelmina Ulle mar³, Yi Lu³, Yunxuan Jiang⁹, 23andMe
Research Team⁹, eQTLGen Consortium¹⁰, BIOS Consortium¹¹, Patrik KE Magnusson³, Robert
Karlsson³, David A Hinds⁹, Lavinia Paternoster¹², Gerard H Koppelman¹³ and Catarina Almqvist^{3,14}

Affiliations

¹ Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia

² Epidemiology, University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands

³ Department of Medical Epidemiology and Biostatistics and the Swedish Twin Registry, Karolinska Institutet, Stockholm, Sweden

⁴ MRC Integrative Epidemiology Unit, Population Health Sciences, University of Bristol, Bristol, UK

⁵ K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway

⁶ Clinic of Thoracic and Occupational Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

⁷ School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom

⁸ Pediatric Allergy and Pulmonology Unit at Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden

⁹ 23andMe, Inc., Mountain View, California, USA

¹⁰ Collaborators of the eQTLGen Consortium are listed at the end of the manuscript.

¹¹ A full list of members and affiliations appears at the end of the manuscript.

¹² MRC Integrative Epidemiology Unit, Population Health Sciences, University of Bristol, Bristol,

UK

¹³ University of Groningen, University Medical Center Groningen, Beatrix Children's Hospital, Pediatric Pulmonology and Pediatric Allergology, and University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands

¹⁴ Pediatric Allergy and Pulmonology Unit at Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden

Corresponding author:

Manuel A R Ferreira, PhD

QIMR Berghofer Medical Research Institute

Locked Bag 2000, Royal Brisbane Hospital,

Herston QLD 4029, Australia

Phone: +61 7 3845 3552

Fax: +61 7 3362 0101

Email: manuel.ferreira@qimrberghofer.edu.au

COMPETING FINANCIAL INTERESTS

Y.J. and D.A.H. are employed by and hold stock or stock options in 23andMe, Inc. All other authors declare no competing financial interests.

ABSTRACT

The extent to which genetic risk factors are shared between childhood-onset (COA) and adult-onset (AOA) asthma has not been estimated. Based on data from the UK Biobank study ($n=447,628$), we found that the variance in disease liability explained by common variants is higher for COA (onset between 0-19; $h^2_g=25.6\%$) than for AOA (onset between 20-60; $h^2_g=10.6\%$). The genetic correlation (r_g) between COA and AOA was 0.67. Variation in age-of-onset amongst COA cases had a low heritability ($h^2_g=5\%$), which we confirmed in independent studies and also amongst AOA cases. To identify subtype-specific genetic associations, we performed a GWAS in the UK Biobank separately for COA (13,962 cases) and AOA (26,582 cases), using a common set of 300,671 controls. We identified 123 independent associations for COA and 56 for AOA (37 overlapped), of which 98 and 34 were reproducible in an independent study ($n=262,767$). Collectively, 28 associations were not previously reported. For 96 COA-associated variants, the risk allele was more common in COA than AOA cases, including five that represent COA-specific risk factors. Conversely, we identified three variants that are stronger risk factors for AOA. Variants associated with obesity and smoking had a stronger contribution to the risk of AOA than of COA. Lastly, we identified 109 likely target genes of the associated variants, based primarily on correlated expression quantitative trait loci (up to $n=31,684$). GWAS informed by age-of-onset can identify subtype-specific risk variants, which can help understand differences in pathophysiology between COA and AOA, and so be informative for drug development.

INTRODUCTION

The age at which asthma (MIM: 600807) symptoms first develop is often used to identify different disease subtypes¹⁻⁷, broadly separating patients into two groups: those with childhood- and adult-onset disease. Perinatal factors, atopy (MIM: 147050), viral respiratory tract infections and the microbiome are thought to play a key role in the development of childhood-onset asthma (COA)⁸⁻¹¹, whereas adult-onset asthma (AOA) is more strongly associated with obesity (MIM: 601665), smoking and other environmental and occupational exposures^{12; 13}. Such differences in aetiology suggest that genetic risk factors might also be partly distinct between COA and AOA. This hypothesis, which to our knowledge has not been formally tested to date, is supported by the observations that asthma risk alleles are enriched amongst cases with early onset disease¹⁴⁻¹⁶. Moreover, it has been shown that the efficacy of novel anti-cytokine asthma therapies, such as anti-IL-5¹⁷ and the anti-IL-5R α ¹⁸, is greater in adult-onset disease, again pointing to age-of-onset-dependent disease mechanisms.

In this study, we used genetic data and information on asthma reported by participants from the UK Biobank study to address three main questions: to what extent do the same genetic variants influence the risk of both COA and AOA? Do genetic variants influence the specific age at which asthma first develops during childhood and during adulthood? Can we identify genetic variants that are risk factors for one disease subtype but not (or less so) the other? Addressing these questions can potentially help understand differences in pathophysiology between patients with COA and AOA, which may have implications for identifying age-of-onset-specific drug targets.

METHODS

Selection of asthma cases from the UK Biobank study

We first identified 53,031 individuals with self-reported doctor-diagnosed asthma amongst 488,365 participants from the UK Biobank study ¹⁹, based on information from three data fields: 6152 (“Has a doctor ever told you that you have had any of the following conditions?”; touchscreen questionnaire), 20002 (verbal interview), 41202 (Diagnoses – main ICD10), 41204 (Diagnoses – secondary ICD10). Specifically, cases had: (i) a report of “Asthma” in field 6152 and a code for asthma in field 20002, or an ICD10 code for asthma in fields 41202 or 41204; and (ii) no report of COPD (MIM: 606963) in fields 6152 or 20002, nor of other respiratory diseases in field 20002. We then excluded 9,984 individuals (leaving 43,047) based on two data fields that recorded information on asthma age-of-onset: 3786 (“What was your age when the asthma was first diagnosed”, touchscreen questionnaire) and 22147 (“Age you were first diagnosed by a doctor”; online follow-up questionnaire, completed only by a subset of participants). Specifically, we excluded asthma cases with (i) missing information for field 3786 ($n=7,393$); (ii) a diagnosis of asthma after the age of 60 (to further minimize potential confounding with COPD; $n=1,723$); or (iii) asthma age-of-onset reported in field 22147 that was >10 years apart from that reported in field 3786 ($n=868$). Lastly, we excluded 2,503 asthmatics who: (i) did not cluster within 5 standard deviations of the mean for the first and second MDS components estimated for individuals from the five European ancestry groups (CEU, GBR, FIN, IBS and TSI) of the 1000 Genomes project, as described previously ¹⁵; (ii) had self-reported sex different from genetically-inferred sex; (iii) were outliers when considering genotype missing rates and/or genome-wide heterozygosity levels; (iv) had more than 10 third degree relatives or were excluded from kinship inference; and/or (v) were not present in the imputed dataset released in July 2017. After these exclusions, there were 40,544 asthmatics available for analysis.

Classification of UK Biobank asthma cases into three groups based on age at first diagnosis

We used the age at first diagnosis reported in fields 3786 and 22147 (average when both available; **Figure S1**) to group the 40,544 asthmatics into three non-overlapping groups, those first diagnosed as a (i) child or teenager, specifically at or before age 19 ($n=13,962$); (ii) young/mid adult, between the ages of 20 and 39 ($n=11,709$); or (iii) older adult, between the ages of 40 and 60 ($n=14,873$). We used a cut-off of age 19 to define childhood-onset asthma so that those diagnosed as an adolescent/teenager (ages 13 to 19; $n=3,164$) were included in the same group as those diagnosed as a child (ages 0 to 12; $n=10,798$). For heritability and genetic correlation analyses, we initially split those diagnosed as adults into two groups because data from longitudinal epidemiological studies show that asthma that is present in early to mid-adult life often has its onset in childhood²⁰⁻²³. As such, those diagnosed between 20 and 39 were expected to represent a more heterogeneous group of asthma cases with respect to the underlying disease course. We used a cut-off of age 39 so that both groups spanned a similar age range (~20 years). We refer to the three case groups as those with childhood-onset asthma (COA), young adult-onset asthma (yAOA) and older adult-onset asthma (oAOA), respectively. Demographics for the three groups are summarized in **Table S1**. The main clinical differences between these groups were a male predominance in COA, with a female predominance of AOA; cases with AOA were also more likely to be obese. Based on results from the heritability and genetic correlation analyses, we then combined the yAOA and oAOA into a single AOA group ($n=26,582$) for genome-wide association analyses.

Variation in asthma liability that is explained by genetic risk factors

We used the BOLT-REML algorithm to estimate the proportion of phenotypic variance in asthma case-control status that was explained by common single nucleotide polymorphisms (SNPs), which we call SNP heritability (h^2_g). This analysis was performed separately for COA, yAOA, oAOA and AOA; controls for these analyses were all other individuals of European ancestry from the UK Biobank study who did not satisfy the specific case definition for each group and passed the quality controls filters described above. Specifically, we identified 433,306 individuals without COA,

435,559 without yAOA, 432,395 without oAOA and 420,686 without AOA. We did not exclude from the control groups individuals who suffered from the other asthma subtypes because this would have resulted in inflated heritability estimates (as a result of excluding controls who suffered from a genetically-correlated trait).

We included as model SNPs in the BOLT-REML analysis ~1 million autosomal SNPs from HapMap3 with minor allele frequency (MAF) >1% and <2% missing rate; discrete (*i.e.* hard-call) genotypes for these SNPs were derived from the ukb_imp_chr[1:22]_v3.bgen files using PLINK v2.00²⁴, with genotype probabilities >0.1 assigned a missing genotype. We included sex and an indicator of the array used for genotyping as covariates. The estimated SNP heritability (and its standard error) was converted to the liability scale using the formula described by Lee et al.²⁵.

Overlap in genetic risk factors between COA and AOA

To determine the extent to which the same genetic risk factors contribute to the risk of childhood- and adult-onset asthma, we used BOLT-REML as described above to estimate the pairwise genetic correlation between COA (13,962 cases and 433,306 controls) and: (i) yAOA (11,709 cases and 435,559 controls); (ii) oAOA (14,873 cases and 432,395 controls); and (iii) AOA (26,582 cases and 420,686 controls). Pairs of genetic correlations were compared statistically using a Z-test. For comparison, genetic correlations were also estimated with a different approach, LD-score regression²⁶, based on association results from ~1 million autosomal SNPs from HapMap3.

To understand if the genetic aetiology of COA and AOA had a comparable allergic component, we used BOLT-REML to estimate the genetic correlation between asthma onset subtypes and a hay fever (MIM: 607154) / eczema (MIM: 603165) combined phenotype created using information provided in data field 6152, which asked “Has a doctor ever told you that you had any of the following conditions?”. When considering individuals of European descent who answered this question and did not meet the exclusion filters described above, 106,782 selected the “Hayfever, allergic rhinitis or eczema” option and so were considered to be cases, while the

remaining 353,418 individuals were considered to be controls.

Contribution of common SNPs to variation in age at first diagnosis

The SNP heritability of age at first diagnosis in the UK Biobank study was estimated separately for COA ($n=13,962$) and AOA ($n=26,582$) cases using BOLT-REML as described above. Age at first diagnosis was quantile-normalized (with ties broken randomly) prior to the BOLT-REML analysis. We also determined if the observed heritability of age-of-onset in UK Biobank COA cases was consistent with that estimated when considering data from 4,718 cases with COA identified in two independent studies described below: the Avon Longitudinal Study of Parents and Children (ALSPAC)²⁷, described in detail in the **Supplemental Methods**, and the Child and Adolescent Twin Study in Sweden (CATSS).

ALSPAC²⁷. We identified 1,326 unrelated children of European descent with a positive response to the question “Did your child have asthma in the past 12 months?” included in surveys completed when the child was approximately 7, 8, 9, 11 or 13 years old. Age-of-onset was defined as the age at which “wheeze” or “wheezing and whistling” was first reported in these surveys. The presence of wheeze was identified based on a positive response to the question: “Has your child had wheezing, breathlessness or episodes of stopping breathing in past 12 months or since he was (age at last Q)?”. “Wheezing and whistling” was identified based on a positive response to the question: “Has your child had any periods when there was wheezing with whistling on his chest when he breathed in past 12 months or since he was (age at last Q)?”. We then performed a GWAS of age-of-onset (quantile-normalized) using SNPTEST with sex included as a covariate; we tested 8.4 million SNPs imputed based on the 1000 Genomes Project reference panel (phase 1, version 3, release Dec 2013).

Child and Adolescent Twin Study in Sweden (CATSS)²⁸. Data on asthma during childhood was collected from parental questionnaires conducted through the Swedish Twin Register for twins born between 1992-1999, completed when the twins were aged 9 and 15. Specifically, the parents

reported the age at which the twins first had asthma/wheezing or breathlessness. This information was supplemented with data from: (i) the National Patient Register (NPR)²⁹, specifically the age at which asthma was first diagnosed by a doctor, based on ICD-10 code J45 or J46, or ICD-9 code 493; and (ii) the Swedish Prescribed Drug Register (SPDG), specifically the age at which the first asthma preventer medication was recorded (ATC codes R03AK, R03BA, R03DC), for anyone with two or more prescriptions before age 20. Asthma age-of-onset was defined as the youngest age across all three data sources (*i.e.* parental questionnaires, NPR and SPDG). After excluding individuals of non-European ancestry, we identified 3,392 twins with asthma onset at or before age 19. DNA samples from these twins were genotyped on the Illumina PsychChip (which includes a GWAS backbone, consisting of 265,000 tag SNPs) and, following sample and SNP quality control (described in the Supplemental Methods), imputed to the 1000 genomes phase 3 reference panel. The association between age-of-onset (quantile-normalized) and SNP allelic dosage was tested with RAREMETALWORKER version 4.13.8, accounting for known relatedness within the sample.

Meta-analysis and estimation of SNP heritability. Age-of-onset GWAS results from the ALSPAC and CATSS studies were combined using an inverse-variance-weighted, fixed-effects meta-analysis, using METAL³⁰. We then applied the LD-score regression approach³¹ to the meta-analysis results to estimate the proportion of variance in age-of-onset explained by common variants, based on 1.1 million HapMap3 SNPs.

Identification of genetic associations with COA and AOA

We performed a GWAS of COA (13,962 cases vs. 300,671 controls) and a GWAS of AOA (26,582 cases vs. 300,671 controls) in the UK Biobank study, using a common set of 300,671 controls who did not suffer from any allergic disease (asthma, hay fever, eczema or other allergies). We used this selected subset of controls for the GWAS, and not the larger set (~430,000) used in the heritability analyses, because the power to detect associations with asthma can be improved by excluding from the control group individuals who suffer from other genetically-correlated allergic diseases³².

To identify the 300,671 non-allergic controls we used information provided on the data fields described above (6152, 20002, 41202, 41204), as well as 22127: “Has a doctor ever told you that you have had any of the conditions below”, which included “Hay fever or allergic rhinitis” and “Asthma” as possible answers. SNPs were tested for association using the linear mixed model implemented in BOLT-LMM³³, which accounted for the presence of related individuals and any residual population stratification amongst Europeans. We included as model SNPs 553,880 autosomal variants that were directly genotyped, had an MAF>1%, call rate >95% and Hardy Weinberg equilibrium P-value >10⁻⁶. Age, sex and an indicator of the genotyping array used were included as discrete covariates.

Of the 92 million variants with imputed data released by the UK Biobank, we retained results for 9 million variants that had (i) a MAF >1%; (ii) matching alleles and were polymorphic in Europeans ($n=294$) of the 1000 Genomes project; (iii) a unique reference sequence (rs) number and genomic position (based on hg19); and (iv) an imputation info score >0.5. For each SNP, the beta and SE was estimated based on a linear model, and so it was subsequently adjusted using the formulae $\text{adj_beta} = \text{beta}/(\mu*(1-\mu))$ and $\text{adj_SE} = \text{SE}/(\mu*(1-\mu))$, where μ is approximated by the case/control ratio. The resulting SE was then inflated by the square root of the LD-score regression³⁴ intercept (respectively 1.039 and 1.018 for COA and AOA), which likely reflects inflation of test statistics due to unaccounted biases, and the association P -value re-calculated using the corrected SE. We used a P -value threshold of 3×10^{-8} for genome-wide significance, as suggested for studies that analyse variants with a MAF >1%³⁵.

As secondary analyses, the same approach was used to perform a GWAS of (i) asthma onset type, specifically comparing COA cases ($n=13,962$, coded as “1”) against AOA cases ($n=14,873$, coded as “0”), *i.e.* a case-only association analysis; and (ii) asthma case-control status, with cases identified irrespective of age at first diagnosis (40,544 cases vs. 300,671 controls; SE and P -value adjusted for an LD-score regression intercept of 1.053). The latter analysis was performed to determine how many associations identified in the COA or AOA GWAS would have been identified

had we instead performed a GWAS of asthma that was not informed by age-of-onset information.

Identification of variants with a statistically independent association with asthma risk

We used the approximate joint association analysis option of GCTA ³⁶ to identify variants that remained associated with asthma risk at a $P < 3 \times 10^{-8}$ in the COA and AOA GWAS after accounting for the effects of nearby (<10 Mb) more strongly associated variants. We refer to these as sentinel risk variants. LD was estimated based on a random subset of 5,000 individuals from the UK Biobank study.

Validation of SNP associations

To determine if SNP associations identified in the UK Biobank study were reproducible, we used the same age cut-offs described above to identify COA cases, AOA cases and allergy-free controls (*i.e.* no asthma, eczema, rhinitis or any other allergic conditions) amongst research participants of the personal genetics company 23andMe, Inc (Supplementary Methods). After restricting the analyses to unrelated individuals of confirmed European descent, sample sizes for the three association analyses performed in the replication study were as follows: (i) 31,759 COA cases vs. 214,890 controls; (ii) 16,297 AOA cases vs. 217,711 controls; and (iii) 31,002 COA cases (coded '1') vs. 16,297 AOA cases (coded '0'). The number of controls was lower in analysis (i) than (ii) because an additional 2,821 controls were relatives of COA cases, and so were excluded from the analysis. Similarly, 757 COA cases were relatives of AOA cases, and so were not included in analysis (iii). Sentinel SNPs identified in the UK Biobank GWAS were tested for association in the 23andMe study using logistic regression, assuming an additive model for allelic effects and including as covariates age, sex and five ancestry-informative principal components. Association results from these analyses were conservatively adjusted for a genomic control inflation factor of 1.101, 1.061 and 1.047, respectively.

Sentinel risk variants not previously implicated in the aetiology of allergic disease

To determine if a sentinel variant was in LD with a SNP previously reported to associate with any allergic disease, we (i) identified all SNPs in LD ($r^2 > 0.05$) with that sentinel variant, using genotype data from individuals of European descent from the 1000 Genomes Project ³⁷ ($n=294$, release 20130502_v5a); and (ii) determined if the sentinel variant or any of the correlated SNPs identified were reported to associate with any allergic disease (asthma, hay fever, eczema, food allergy or atopy) in the NHGRI-EBI GWAS catalog database ³⁸, which was downloaded on the 30th of September 2018.

Genetic correlation between COA and AOA and other complex diseases/traits

To provide some insight into potential differences in genetic aetiology between COA and AOA, we used the LD-score regression approach to estimate the pairwise genetic correlation between each disease subtype and 227 common traits or diseases with GWAS data currently available in LD Hub ³⁹. We uploaded to LD Hub association results from ~1.1 million HapMap3 SNPs, obtained when comparing 13,962 cases vs. 433,306 controls for COA, and 26,582 cases vs. 420,686 controls for AOA, as done in the BOLT-REML analysis.

Predicting target genes of sentinel variants based on LD with eQTL and non-synonymous SNPs

We performed the following steps to identify genes for which variation in gene expression and/or protein sequence was associated with sentinel SNPs identified in the COA and AOA GWAS.

First, we identified SNPs associated with variation in gene expression (i.e. expression quantitative trait loci, eQTL) in published transcriptome studies of five broad tissue types relevant for asthma: individual immune cell types, lung, skin, spleen and whole-blood. We identified a total of 50 transcriptome studies reporting results from eQTL analyses in any one of those five tissue types (**Table S2**). Some studies included multiple cell types, experimental conditions and/or eQTL

types, resulting in a total of 130 separate eQTL datasets. For each eQTL dataset, we then (i) downloaded the original publication tables/files containing results for the eQTL reported; (ii) extracted the SNP identifier, gene name, association P-value and directional effect (if available; beta/z-score and effect allele); (iii) excluded eQTL located >1 Mb of the respective gene (i.e. *trans* eQTL), because often these are thought to be mediated by *cis* effects⁴⁰; (iv) excluded eQTL with an association $P > 8.9 \times 10^{-10}$, a conservative threshold that corrects for 55,765 genes (based on GENCODE v19), each tested for association with 1,000 SNPs (as suggested by others⁴¹⁻⁴³); and (v) for each gene, used the --clump procedure in PLINK²⁴ to reduce the list of eQTL identified (which often included many correlated SNPs) to a set of ‘sentinel eQTL’, defined as the SNPs with strongest association with gene expression and in low LD ($r^2 < 0.05$, linkage disequilibrium (LD) window of 2 Mb) with each other.

Second, we identified genes for which a sentinel eQTL reported in any of the 130 eQTL datasets described above was in high LD ($r^2 > 0.8$) with a sentinel variant identified in the COA or AOA GWAS. That is, we only considered genes for which there was high LD between a sentinel eQTL and a sentinel asthma risk variant, which reduces the chance of spurious co-localization.

Third, we used wANNOVAR⁴⁴ to identify genes containing non-synonymous SNPs amongst all variants in LD ($r^2 > 0.8$) with any sentinel variants. SNPs in LD with sentinel variants were identified using genotype data from individuals of European descent from the 1000 Genomes Project³⁷ ($n=294$, release 20130502_v5a).

Ethical approval for the study was obtained from the Human Ethics Committee of the QIMR Berghofer Medical Research Institute; and the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees.

RESULTS

Overlap in genetic risk factors between childhood- and adult-onset asthma

When cases in the UK Biobank study were defined as asthmatics who reported disease onset as a child (age 0 to 19, $n=13,962$; demographics in **Table S1**) and controls as all other individuals ($n=433,306$), the liability scale SNP heritability (h^2_g) estimated with the BOLT-REML algorithm⁴⁵ was 25.6% (SE=0.67%; **Table 1**). Substantially lower SNP heritability estimates were obtained when considering asthmatics who reported developing asthma as a young (age 20 to 39; 11,709 cases vs. 435,559 controls) or older (age 40 to 60; 14,873 cases vs. 432,395 controls) adult: $h^2_g=9.8\%$ (SE=0.59%) and $h^2_g=7.8\%$ (SE=0.49%), respectively (**Table 1**).

We then estimated the extent to which the same genetic risk factors contributed to the heritability of childhood- and adult-onset asthma. Using BOLT-REML, we observed a modest genetic correlation ($r_g=0.47$, SE=0.03; **Table 1**) between childhood-onset asthma (COA) and older adult-onset asthma (oAOA). Similar results were obtained with the LD-score regression approach ($r_g=0.42$, SE=0.06). In contrast, larger genetic correlations were observed between young adult-onset asthma (yAOA) and both COA ($r_g=0.83$, SE=0.03) and oAOA ($r_g=0.86$, SE=0.05).

The large genetic correlation observed between yAOA and oAOA, together with their similar heritability estimates, suggests that most SNPs associated with disease risk in adult-onset asthma have broadly similar allele frequencies in yAOA and oAOA cases. This is not the case between COA and yAOA, nor between COA and oAOA, given the large differences in SNP heritability and, in the case of oAOA, also the modest pairwise genetic correlation. For these reasons, we then combined the yAOA and oAOA cases into a single group with AOA ($n=26,582$). When we compared AOA cases against all other individuals as controls ($n=420,686$), we observed a SNP heritability on the liability scale of 10.6% (SE=0.38%), with a genetic correlation with COA estimated to be 0.67 (SE=0.023; **Table 1**). Similar results were obtained with LD-score regression ($r_g=0.63$, SE=0.054). These results show that the genetic correlation between COA and AOA is

significantly lower than 1 ($P=10^{-46}$).

To investigate if the genetic aetiology of COA had a larger allergic component than AOA, we then estimated their pairwise genetic correlation with a combined hay fever/eczema phenotype measured in the same UK Biobank participants ($n=447,268$). Using BOLT-REML, we found that genetic risk factors for hay fever/eczema ($h^2_g=15.6\%$, $SE=0.26\%$) significantly overlapped those for both COA and AOA, but the overlap was larger for the former: $r_g=0.70$ ($SE=0.013$) vs. $r_g=0.57$ ($SE=0.017$). Similar results were obtained when considering doctor-diagnosed hay fever ($r_g=0.67$ vs. $r_g=0.56$), which was available for a subset of UK Biobank individuals ($n=111,664$).

Collectively, these results demonstrate that in the UK Biobank study, asthma reported to first develop as a child has a genetic architecture that is partly similar and partly distinct from asthma reported to first develop as an adult.

Contribution of common SNPs to variation in age at first diagnosis amongst cases with COA and AOA

Next, we used BOLT-REML to test if common SNPs also influenced the specific age at which asthma was diagnosed during childhood and, separately, during adulthood. We first performed this analysis in the 13,962 cases with COA in the UK Biobank study. We found that only 5.1% ($SE=2.2\%$) of the variance in self-reported asthma age-of-onset was explained by common SNPs, an estimate that was borderline significantly greater than 0% ($P=0.011$). Similar results were obtained using the GCTA-GREML approach (4.5%, $SE=2.2\%$, $P=0.017$). To confirm this finding, we then performed the same analysis in two independent studies conducted in children: ALSPAC ($n=1,326$) and CATSS ($n=3,392$), for a combined sample size of 4,718 cases with COA. We obtained a similarly low estimate of SNP heritability (3.0%, $SE=9.3\%$) in this combined dataset using the LD-score regression approach²⁶. Similar results were also obtained when considering the 26,582 individuals from the UK Biobank study with AOA (onset between 20 and 60): $h^2_g=4.4\%$ ($SE=1.2\%$). These findings indicate that common SNPs explain only a small amount of variation in

self-reported age-of-onset amongst COA and AOA cases.

Identification and validation of genetic associations with COA and AOA

We then set out to identify genetic risk factors for COA and AOA separately. In a GWAS of COA (**Figure 1** and **Figure S2**), which included 13,962 cases and 300,671 controls from the UK Biobank study who did not report any allergic disease (*i.e.* individuals without asthma, hay fever, eczema or other allergies), we identified 123 SNPs with an independent association with disease risk at a $P < 3 \times 10^{-8}$ (which we call sentinel SNPs; **Table S3**), located in 83 loci $> 1\text{Mb}$ apart. In a separate GWAS of AOA (26,582 cases and the same 300,671 controls; **Figure 1** and **Figure S3**), we identified 56 sentinel risk SNPs (in 40 loci), including 19 that were in low LD ($r^2 < 0.05$) with COA sentinel variants (**Table S4**). Consistent associations for all sentinel variants were observed when individuals with hay fever, eczema or other allergies were not excluded from the control group (**Figure S4**).

Overall, 27/123 (22%) COA and 5/56 (9%) AOA associations would not have been identified at the genome-wide significance level had we compared all asthma cases (*i.e.* irrespective of age-of-onset, $n=40,544$) against the same 300,671 controls (**Tables S5 and S6**). For example, the COA variant rs9391997 (in *IRF4* [MIM:601900]) had only a modest association with asthma risk when considering all asthma cases ($\text{OR}=1.02$, $P=0.001$).

To replicate the associations identified, we used data from research participants of the personal genetics company 23andMe, Inc. Using the same age cut-offs as for the UK Biobank study, and after restricting the analyses to unrelated individuals of confirmed European descent, there were 31,759 COA cases and 214,890 asthma- and allergy-free controls. Of the 123 sentinel SNPs identified in the UK Biobank GWAS of COA, 108 were available for replication, of which 98 had both a (1) reproducible association ($P < 0.05$ and same direction of effect) in the independent 23andMe study *per se*; and (2) a genome-wide significant association in the meta-analysis of the UK Biobank and 23andMe studies (45,721 COA cases vs. 515,561 controls; **Table 1** and **Table S7**).

For AOA, data were available for 16,297 cases and 217,711 controls in the 23andMe study. Using the same criteria, 34 (of 46 tested) sentinel SNPs for AOA were associated with disease risk in the 23andMe study and in the overall meta-analysis (42,879 cases vs. 518,382 controls; **Table 2** and **Table S8**).

Shared or disease onset-specific SNP associations?

To formally test if the 132 (98+34) SNP associations identified differed between COA and AOA, for each sentinel variant we compared the frequency of the risk allele between COA and AOA cases. Based on combined results from the UK Biobank and 23andMe studies (44,964 COA cases vs. 42,879 AOA cases), we found that the risk allele was more common in COA than AOA cases for all 98 COA sentinel variants, significantly so for 96 SNPs ($P < 0.05$; **Table S9**). Therefore, most if not all 98 COA sentinel SNPs are stronger risk factors for COA than for AOA. At least five sentinel SNPs are likely to represent COA-specific risk factors (**Figure 2A**), because they were not associated with AOA risk (OR~1 in the meta-analysis of UK Biobank and 23andMe studies; **Table S9**).

A similar pattern of results was observed for 31 of the 34 sentinel SNPs identified for AOA (**Table S10**), that is, the risk allele was observed at a significantly higher (22 SNPs) or similar (nine SNPs) frequency in COA than AOA cases. For the remaining three AOA sentinel SNPs (rs2381712 near *TEX41*, rs2544026 in *HDAC7* [MIM: 606542] and rs28635831 in *COG6* [MIM: 606977]), we observed a different pattern of results: the risk allele was significantly more common in AOA than COA cases, suggesting that they are stronger risk factors for AOA. Notably, one of these SNPs is likely to represent an AOA-specific risk factor, given the lack of association with COA (OR~1): rs2381712 near *TEX41* (**Figure 2B** and **Table S10**).

Of the seven SNPs reported in two GWAS of asthma age-of-onset published previously {Sarnowski, 2016; Forno, 2012} – located in/near *IL1RL1*, *HLA-DQA1*, *IL33*, *CYLD*, *GSDMB*, *CRBN* and *ETSI* – six were tested in our analysis, with four having a consistent association (**Table**

S11). The two variants for which the reported association was not supported by results from our analysis were located in/near *CYLD* and *CRBN*; both were not associated with asthma onset type (**Table S11**), nor COA or AOA risk (not shown).

Sentinel variants not reported in previous GWAS of asthma or other allergic diseases

We determined which of the 132 sentinel variants identified above represented novel associations for allergic disease in general, that is, when considering all previously reported associations with $P < 5 \times 10^{-8}$ for asthma, hay fever, eczema, food allergy and/or atopy. Of the 98 sentinel variants confirmed for COA, 73 were in LD ($r^2 > 0.05$) with variants previously reported to associate with allergic disease (**Table S12**), while the remaining 25 represent novel SNP associations at the genome-wide significance level (**Table 1**). Of the 34 sentinel associations for AOA, 28 have previously been described (**Table S13**), but six were novel (**Table 2**), including three not discovered in our GWAS of COA (in/near *PTPRC* [MIM: 151460], *TEX41* and *COG6*). Therefore, overall we identified 28 (25+3) novel associations for asthma.

Genetic correlation between COA and AOA and other complex diseases/traits

To provide some clues into the potential differences in genetic aetiology between COA and AOA, we estimated the overlap in genetic risk factors between COA and AOA and 227 human traits or diseases with publicly available GWAS results, using LD Hub³⁹. We observed a number of genetic correlations that were significantly different from 0 (at a $P < 0.05/227 = 0.0002$; **Table S14**), of which we highlight three groups. First, significant correlations with a similar magnitude between COA and AOA were observed for lung function traits, for example FEV₁/FVC ($r_g = -0.35$ for both). Because the SNP heritability of COA was larger than that of AOA, these results indicate that genetic variants that influence variation in lung function explain a larger proportion of variation in disease risk for COA than for AOA. Second, the genetic correlation was significant with COA but not with AOA for two traits: eczema ($r_g = 0.60$ vs. $r_g = 0.04$) and years of schooling ($r_g = 0.11$ vs. $r_g = -0.09$). Lastly, the

genetic correlation was significant with AOA but not with COA for six sets of traits: (i) obesity-related traits (*e.g.* being overweight, $r_g=0.08$ vs. $r_g=0.28$); (ii) age when first child was born ($r_g=0.07$ vs. $r_g=-0.27$); (iii) ever smoker ($r_g=-0.07$ vs. $r_g=0.23$); (iv) rheumatoid arthritis ($r_g=-0.09$ vs. $r_g=0.18$; [MIM: 180300]); (v) insomnia ($r_g=-0.03$ vs. $r_g=0.21$); and (vi) depressive symptoms ($r_g=0.02$ vs. $r_g=0.19$).

Likely target genes of the sentinel risk variants

Finally, we found that 11 sentinel variants were in high LD ($r^2 \geq 0.8$) with missense or non-synonymous SNPs in 12 genes, including four with variants that were predicted to have a damaging effect on the protein by both SIFT and PolyPhen-2: *HLA-C*, *ITGB8*, *NOD2* and *TESPA1* (**Table S15**). On the other hand, 62 sentinel variants were in high LD with a sentinel eQTL associated with gene expression in disease-relevant tissues or cell types at a conservative $P < 8.9 \times 10^{-10}$ (**Table S2**), implicating an additional 97 genes as likely targets of asthma risk variants (**Tables S16 and S17**). Of the 109 genes (12+97; **Table S18**), 25 were the predicted targets of novel sentinel risk SNPs for asthma (**Table 3**), of which we highlight seven based on a stricter LD threshold ($r^2 > 0.95$): *CCL20* (rs10187276; [MIM: 601960]); *IL2RA* (rs12722502; [MIM: 147730]); *PRKCQ* (rs943451; [MIM: 600448]); *PRR5L* (rs10836538; [MIM: 611728]); *CCR12P* (rs4771332); *TESPA1* (rs62623446; [MIM: 615664]); *NSMCE1* (rs3785356; [MIM: 617263]); *NOD2* (rs2066844; [MIM: 605956]); *RP11-729L2.2* and *SMAD4* (rs1893380; [MIM: 600993]); and *GPX4* (rs892225; [MIM: 138322]).

DISCUSSION

We found that in the UK Biobank study (i) common genetic variants collectively explain a larger fraction of variation in liability to COA than AOA; (ii) the genetic correlation between COA and AOA is high but significantly different from 1; and (iii) variation in the specific age at which asthma first develops within each asthma subtype has a low SNP heritability. We also identified and validated 98 independent genetic associations for COA and 34 for AOA, and 109 likely target genes of the risk variants.

The observed difference in SNP heritabilities between COA and AOA, together with a genetic correlation that was significantly different from 1, indicates that the genetic architectures of COA and AOA are similar but not identical. Exactly how they might differ is unclear, as the observed heritabilities and genetic correlation might arise under different scenarios. For example, a genetic correlation different from 1 might arise not only when there are subtype-specific risk variants (*i.e.* associated with one disease subtype but not the other) but, in some situations, even when all risk variants are shared between COA and AOA, as shown by Carey et al.⁴⁶. Specifically, a genetic correlation will be lower than 1 even when all risk loci are shared if there is little (or no) correlation in genetic effects between the two diseases. The latter scenario is relatively extreme, and is not supported from results of our GWAS, which found evidence for subtype-specific associations. A more realistic scenario is that for some variants, genetic effects are highly correlated between COA and AOA, and so these contribute to a higher genetic correlation. In contrast, other variants might have subtype-specific associations, or genetic effects that are weakly correlated between COA and AOA; such variants would contribute to a lower genetic correlation. Under such model, where the correlation in genetic effects differs between groups of variants, on balance the genetic correlation between COA and AOA would be high but significantly different from 1. Association results for the sentinel SNPs identified in our GWAS suggest that this model is plausible (**Figure 2**).

The observation that COA and AOA have partly distinct genetic architectures is perhaps surprising given their broad similarity in clinical presentation. For comparison, COA had a similar

genetic overlap with a combined hay fever/eczema phenotype ($r_g=0.7$) as it did with AOA. We speculate that these results imply that there may be distinct genes or molecular pathways involved in COA but not (or less so) in AOA, or vice-versa, in which case identifying such pathways could inform the development of drugs tailored specifically for COA or AOA. Another possibility, however, is that a particular gene contributes to the pathophysiology of both disease subtypes, with its expression being dysregulated in COA and AOA cases by different mechanisms: inherited risk alleles in the former and acquired epigenetic modifications in the latter. Such epigenetic modifications in AOA cases could potentially result from long-term exposure to environmental risk factors, such as a low-quality diet ⁴⁷ or smoking ⁴⁸. For example, we recently highlighted that lower expression of *PITPNM2* (MIM: 608920), a gene potentially involved in neutrophil function, is independently associated with an allergy-predisposing allele and smoking-induced CpG methylation ¹⁵. Studies that carefully investigate the contribution of epigenetic modifications to the aetiology of asthma, particularly with adult onset, are warranted; we suggest to first investigate genes implicated by genetic studies.

Results from our heritability analysis also indicate that common SNPs explain only about 5% of the variation in the specific age at which asthma was reported to be diagnosed during childhood and during adulthood. This observation, together with the widespread allele frequency differences observed between COA and AOA cases, indicates that SNP associations discovered when analyzing the full spectrum of age-of-onset (*i.e.* spanning early childhood to older adulthood) must be interpreted with care. Specifically, it should be considered if a specific association is likely to reflect allele frequency differences between cases with different asthma onset subtypes (*e.g.* COA vs. AOA), or between cases with the same asthma subtype (*e.g.* COA) but with different age-of-onset. Our results suggest that the former scenario will be more common than the latter. By extension, our findings also suggest that measurement error and/or environmental risk factors have the largest contribution to variation in specific age-of-onset within each disease subtype. In childhood, candidate environmental risk factors that might affect age-of-onset include the timing,

frequency and duration of chest infections, allergen exposure, pet ownership, maternal smoking and low-quality diet during pregnancy ⁴⁹⁻⁵⁵. In adulthood, additional risk factors might include occupational exposures, active smoking and obesity ^{20; 22; 56-58}.

To identify genetic risk factors that could be specific to COA or AOA, we performed two GWAS in the UK Biobank study, separately comparing 13,962 COA cases and 26,582 AOA cases against a common set of 300,671 asthma and allergy-free controls. Despite a relatively small case sample size in the GWAS of COA, we identified a large number of independent SNP associations with asthma risk, 123 in total. A relatively smaller number of associations (56) were identified in the GWAS of AOA, consistent with the lower overall SNP heritability estimated for this disease subtype. For comparison, the largest number of independent associations reported to date in a single GWAS of asthma was 27 (based on 28,399 cases and 128,843 controls ⁵⁹).

To validate the observed associations, we repeated the association analyses in the independent 23andMe study, comprising a total of 265,767 individuals. Of the 179 (123+56) associations discovered in the UK Biobank study, 132 (98+34) were also detected in the replication study, and remained genome-wide significant in the combined analysis. Taking into account all associations reported to date for allergy-related traits in the GWAS catalog ⁶⁰, and based on a conservative LD r^2 threshold of 0.05, 28 of the combined 132 sentinel risk SNPs were found to represent novel associations for asthma. Amongst these were the first two genome-wide significant associations for asthma reported for variants on the X-chromosome: rs850637, which overlaps a predicted transcription factor binding site for RELA and is located between *TLR7* (MIM: 300365) and *TLR8* (MIM: 300366), two genes involved in anti-viral immunity⁶¹⁻⁶³; and rs5953283 located 18 kb upstream of *FOXP3* (MIM: 300292), which is central to the establishment and maintenance of regulatory T cells ⁶⁴.

To determine if the associations with COA and AOA were likely to be subtype-specific, we then compared the frequency of the disease-predisposing allele for each sentinel risk SNP between the COA and AOA cases. We found that for most sentinel SNPs, identified in either the COA or

AOA GWAS, the predisposing allele was significantly more common in COA than AOA cases, consistent with a stronger association with COA. This includes five variants that are likely to represent COA-specific risk factors, because the frequency of the predisposing allele was similar in AOA cases compared to non-asthmatic controls (*i.e.* OR~1 in the GWAS of AOA). Based on LD with sentinel eQTLs and non-synonymous variants, we were able to identify a likely target gene for only one of these five COA-specific risk variants (rs4574025): *PIGN* (MIM: 606097), a component of the glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway ⁶⁵, which is involved in anchoring proteins to the cell surface ⁶⁶ and in ATP release ⁶⁷.

We also found one example of a sentinel SNP that is likely to represent an AOA-specific risk factor: rs2381712 near *TEX41*, which encodes a long non-coding RNA. Of note, rs2381712 is in moderate LD ($r^2=0.41$; $D'=0.75$) with a variant (rs10193706) reported to associate with smoking behavior (heavy vs. never smokers) ⁶⁸. The rs10193706:C allele that was associated with being a heavy smoker was associated with a lower risk of AOA, which is unexpected given that smoking is thought to be a risk factor for AOA and the overall positive genetic correlation that we observed between smoking behavior and AOA risk. As such, it is possible that the two associations (rs2381712 with AOA, and rs10193706 with smoking) do not tag the same underlying causal variant. We did not find any sentinel eQTLs or non-synonymous SNPs in high LD with rs2381712, and so the likely target gene of this risk variant remains to be identified. A nearby gene of potential interest to asthma is *ZEB2* (MIM: 605802), which encodes a transcription factor that regulates T cell and dendritic cell development ⁶⁹⁻⁷¹, as well as mast cell signaling ⁷².

For two additional sentinel SNPs, the observed difference in risk allele frequency between the two case groups (AOA > COA) suggests that they represent stronger risk factors for AOA: rs2544026 in *HDAC7* and rs28635831 in *COG6*. *HDAC7* was identified as a likely target gene of rs2544026 based on eQTL information from macrophages exposed to live bacterial pathogens (*Listeria* and *Salmonella*), with results consistent between two different eQTL studies ^{73; 74}. Specifically, in infected macrophages but not in non-infected cells, the rs2544026:T disease-

predisposing allele was associated with lower *HDAC7* expression. This observation is consistent with reduced overall HDAC activity in patients with asthma^{75; 76} and COPD⁷⁷. How lower *HDAC7* expression in infected macrophages might then result in a higher risk of asthma needs to be determined. Because *HDAC7* is thought to be a repressor of macrophage-specific genes⁷⁸, one possibility is that lower *HDAC7* expression in macrophages results in a more exuberant inflammatory response against bacterial infections, which might contribute to an asthma-prone environment in the airways. Interestingly, *COG6* was also identified as a likely target of rs28635831 based solely on eQTLs described in macrophages stimulated with *Salmonella*⁸¹. Variants in moderate to high LD with rs28635831 have been reported to associate with auto-immune diseases, namely psoriasis (MIM: 177900)⁷⁹, rheumatoid arthritis and lupus erythematosus (MIM: 152700)⁸⁰. *COG6* is part of the conserved oligomeric Golgi complex, with mutations in this gene described in patients with congenital disorders of glycosylation; core clinical features include recurrent infections and hyperkeratosis⁸¹. These observations suggest that *COG6* might play a role in immune cell function; studies that address this possibility are warranted.

Results from the genetic correlation analysis between COA/AOA and other complex traits/diseases provided some clues into disease mechanisms that are dysregulated by genetic variants in one disease subtype but not (or less so) in the other. First, we found a larger genetic correlation with eczema for COA than AOA. This observation, which supported findings from the genetic correlation analysis with hay fever that we performed in the UK Biobank study, indicates that SNPs that influence molecular pathways underlying allergies explain a larger proportion of variation in disease risk for COA than for AOA. Second, we found that alleles associated with achieving a higher education level were collectively associated with a higher risk of COA, consistent with some epidemiological studies^{82; 83}, but a lower risk of AOA. These opposing effects suggest that different mechanisms underlie both associations. For example, on the one hand, the development of asthma in childhood might result in an increased preference later in life for a professional career that requires a higher education. On the other hand, higher education is

associated with a lower BMI in adulthood⁸⁴, which is protective for asthma. These potential causal relationships and other possible explanations (*e.g.* genetic pleiotropy) for the observed genetic correlations with education attainment should be explored in future studies. Lastly, we found that variants associated with three risk factors for asthma – obesity, smoking and age at first birth (or puberty) – had a stronger contribution to the risk of AOA than of COA. As highlighted above, a significant genetic correlation might arise because of a causal effect of these risk factors on asthma risk⁸⁵⁻⁸⁸. At least for obesity, such causal effect does not appear to extend to other allergies⁸⁹, which could potentially explain the difference in genetic correlation between AOA and COA.

A caveat of our analysis is that some asthma cases from the UK Biobank included in the AOA group might not have recollected a physician's diagnosis of asthma as a child. Such misclassification of true COA as AOA would tend to inflate the estimate of the genetic correlation between COA and AOA, and also to decrease power to detect AOA-specific SNP associations.

In conclusion, we show that childhood-onset asthma has a genetic aetiology that is partly distinct from asthma that first develops in adult life. GWAS informed by age-of-onset can identify subtype-specific genetic risk factors, which can help understand differences in pathophysiology between childhood and adult asthma.

DESCRIPTION OF SUPPLEMENTAL DATA

Supplemental data include four figures and 15 tables.

ACKNOWLEDGMENTS

This research has been conducted using the UK Biobank Resource (application 10074). MARF was supported by a Senior Research Fellowship (APP1124501) from the National Health and Medical Research Council (NHMRC) of Australia. LP was funded by a UK MRC fellowship award (MR/J012165/1) and works in a unit funded by the UK MRC (MC_UU_12013).

23andMe: We would like to thank the research participants and employees of 23andMe for making this work possible. We particularly thank the following members of the 23andMe Research Team: Michelle Agee, Babak Alipanahi, Adam Auton, Robert K. Bell, Katarzyna Bryc, Sarah L. Elson, Pierre Fontanillas, Nicholas A. Furlotte, Barry Hicks, Karen E. Huber, Ethan M. Jewett, Aaron Kleinman, Keng-Han Lin, Nadia K. Litterman, Matthew H. McIntyre, Kimberly F. McManus, Joanna L. Mountain, Elizabeth S. Noblin, Carrie A.M. Northover, Steven J. Pitts, G. David Poznik, J. Fah Sathirapongsasuti, Janie F. Shelton, Suyash Shringarpure, Chao Tian, Joyce Y. Tung, Vladimir Vacic, Xin Wang, Catherine H. Wilson.

CATSS: We acknowledge The Swedish Twin Registry for access to data. The Swedish Twin Registry is managed by Karolinska Institutet and receives funding through the Swedish Research Council under the grant no 2017-00641. Financial support was provided from the Swedish Research Council through the Swedish Initiative for Research on Microdata in the Social And Medical Sciences (SIMSAM) framework grant no 340-2013-5867, grants provided by the Stockholm County Council (ALF-projects), the Swedish Heart-Lung Foundation and the Swedish Asthma and Allergy Association's Research Foundation.

ALSPAC: We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers,

managers, receptionists and nurses. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe.

WEB RESOURCES

The URLs for data presented herein are as follows:

OMIM, <https://www.omim.org/>

Summary statistics from GWAS of COA and AOA in the UK Biobank, https://genepi.qimr.edu.au/staff/manuef/gwas_results/main.html

REFERENCES

1. Tan, D.J., Walters, E.H., Perret, J.L., Lodge, C.J., Lowe, A.J., Matheson, M.C., and Dharmage, S.C. (2015). Age-of-asthma onset as a determinant of different asthma phenotypes in adults: a systematic review and meta-analysis of the literature. *Expert Rev Respir Med* 9, 109-123.
2. Moore, W.C., Meyers, D.A., Wenzel, S.E., Teague, W.G., Li, H., Li, X., D'Agostino, R., Jr., Castro, M., Curran-Everett, D., Fitzpatrick, A.M., et al. (2010). Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *Am J Respir Crit Care Med* 181, 315-323.
3. Deliu, M., Yavuz, T.S., Sperrin, M., Belgrave, D., Sahiner, U.M., Sackesen, C., Kalayci, O., and Custovic, A. (2018). Features of asthma which provide meaningful insights for understanding the disease heterogeneity. *Clin Exp Allergy* 48, 39-47.
4. Newby, C., Heaney, L.G., Menzies-Gow, A., Niven, R.M., Mansur, A., Bucknall, C., Chaudhuri, R., Thompson, J., Burton, P., Brightling, C., et al. (2014). Statistical cluster analysis of the British Thoracic Society Severe refractory Asthma Registry: clinical outcomes and phenotype stability. *PLoS One* 9, e102987.
5. Wu, W., Bleecker, E., Moore, W., Busse, W.W., Castro, M., Chung, K.F., Calhoun, W.J., Erzurum, S., Gaston, B., Israel, E., et al. (2014). Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. *J Allergy Clin Immunol* 133, 1280-1288.
6. Kim, T.B., Jang, A.S., Kwon, H.S., Park, J.S., Chang, Y.S., Cho, S.H., Choi, B.W., Park, J.W., Nam, D.H., Yoon, H.J., et al. (2013). Identification of asthma clusters in two independent Korean adult asthma cohorts. *Eur Respir J* 41, 1308-1314.
7. Haldar, P., Pavord, I.D., Shaw, D.E., Berry, M.A., Thomas, M., Brightling, C.E., Wardlaw, A.J., and Green, R.H. (2008). Cluster analysis and clinical asthma phenotypes. *Am J Respir Crit Care Med* 178, 218-224.
8. Ortqvist, A.K., Lundholm, C., Carlstrom, E., Lichtenstein, P., Cnattingius, S., and Almqvist, C. (2009). Familial factors do not confound the association between birth weight and childhood asthma. *Pediatrics* 124, e737-743.
9. Tedner, S.G., Ortqvist, A.K., and Almqvist, C. (2012). Fetal growth and risk of childhood asthma and allergic disease. *Clin Exp Allergy* 42, 1430-1447.
10. Holt, P.G. (2015). The mechanism or mechanisms driving atopic asthma initiation: The infant respiratory microbiome moves to center stage. *J Allergy Clin Immunol* 136, 15-22.
11. Lynch, J.P., Sikder, M.A., Curren, B.F., Werder, R.B., Simpson, J., Cuiv, P.O., Dennis, P.G., Everard, M.L., and Phipps, S. (2017). The Influence of the Microbiome on Early-Life Severe Viral Lower Respiratory Infections and Asthma-Food for Thought? *Front Immunol* 8, 156.
12. de Nijs, S.B., Venekamp, L.N., and Bel, E.H. (2013). Adult-onset asthma: is it really different? *Eur Respir Rev* 22, 44-52.
13. Ilmarinen, P., Tuomisto, L.E., and Kankaanranta, H. (2015). Phenotypes, Risk Factors, and Mechanisms of Adult-Onset Asthma. *Mediators Inflamm* 2015, 514868.
14. Sarnowski, C., Sugier, P.E., Granell, R., Jarvis, D., Dizier, M.H., Ege, M., Imboden, M., Laprise, C., Khusnutdinova, E.K., Freidin, M.B., et al. (2016). Identification of a new locus at 16q12 associated with time to asthma onset. *J Allergy Clin Immunol* 138, 1071-1080.
15. Ferreira, M.A., Vonk, J.M., Baurecht, H., Marenholz, I., Tian, C., Hoffman, J.D., Helmer, Q., Tillander, A., Ullema, V., van Dongen, J., et al. (2017). Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. *Nat Genet* 49, 1752-1757.
16. Belsky, D.W., Sears, M.R., Hancox, R.J., Harrington, H., Houts, R., Moffitt, T.E., Sugden, K., Williams, B., Poulton, R., and Caspi, A. (2013). Polygenic risk and the development and course of asthma: an analysis of data from a four-decade longitudinal study. *The Lancet Respiratory medicine* 1, 453-461.
17. Brusselle, G., Germinaro, M., Weiss, S., and Zangrilli, J. (2017). Reslizumab in patients with

inadequately controlled late-onset asthma and elevated blood eosinophils. *Pulm Pharmacol Ther* 43, 39-45.

18. Bleecker, E.R., Wechsler, M.E., FitzGerald, J.M., Menzies-Gow, A., Wu, Y., Hirsch, I., Goldman, M., Newbold, P., and Zangrilli, J.G. (2018). Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. *Eur Respir J* 52.
19. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2017). Genome-wide genetic data on ~500,000 UK Biobank participants. *bioRxiv*.
20. Strachan, D.P., Butland, B.K., and Anderson, H.R. (1996). Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. *BMJ* 312, 1195-1199.
21. Oswald, H., Phelan, P.D., Lanigan, A., Hibbert, M., Bowes, G., and Olinsky, A. (1994). Outcome of childhood asthma in mid-adult life. *BMJ* 309, 95-96.
22. Sood, A., Qualls, C., Schuyler, M., Arynchyn, A., Alvarado, J.H., Smith, L.J., and Jacobs, D.R., Jr. (2013). Adult-onset asthma becomes the dominant phenotype among women by age 40 years. the longitudinal CARDIA study. *Annals of the American Thoracic Society* 10, 188-197.
23. Jenkins, M.A., Hopper, J.L., Bowes, G., Carlin, J.B., Flander, L.B., and Giles, G.G. (1994). Factors in childhood as predictors of asthma in adult life. *BMJ* 309, 90-93.
24. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience* 4, 7.
25. Lee, S.H., Wray, N.R., Goddard, M.E., and Visscher, P.M. (2011). Estimating missing heritability for disease from genome-wide association studies. *Am J Hum Genet* 88, 294-305.
26. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.R., ReproGen, C., Psychiatric Genomics, C., Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control, C., Duncan, L., et al. (2015). An atlas of genetic correlations across human diseases and traits. *Nat Genet* 47, 1236-1241.
27. Boyd, A., Golding, J., Macleod, J., Lawlor, D.A., Fraser, A., Henderson, J., Molloy, L., Ness, A., Ring, S., and Davey Smith, G. (2013). Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and Children. *Int J Epidemiol* 42, 111-127.
28. Anckarsater, H., Lundstrom, S., Kollberg, L., Kerekes, N., Palm, C., Carlstrom, E., Langstrom, N., Magnusson, P.K., Halldner, L., Bolte, S., et al. (2011). The Child and Adolescent Twin Study in Sweden (CATSS). *Twin Res Hum Genet* 14, 495-508.
29. Magnusson, P.K., Almqvist, C., Rahman, I., Ganna, A., Viktorin, A., Walum, H., Halldner, L., Lundstrom, S., Ullen, F., Langstrom, N., et al. (2013). The Swedish Twin Registry: establishment of a biobank and other recent developments. *Twin Res Hum Genet* 16, 317-329.
30. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 26, 2190-2191.
31. Bulik-Sullivan, B.K., Loh, P.R., Finucane, H.K., Ripke, S., Yang, J., Schizophrenia Working Group of the Psychiatric Genomics, C., Patterson, N., Daly, M.J., Price, A.L., and Neale, B.M. (2015). LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* 47, 291-295.
32. Ferreira, M.A. (2014). Improving the power to detect risk variants for allergic disease by defining case-control status based on both asthma and hay fever. *Twin Res Hum Genet* 17, 505-511.
33. Loh, P.R., Tucker, G., Bulik-Sullivan, B.K., Vilhjalmsdottir, B.J., Finucane, H.K., Salem, R.M., Chasman, D.I., Ridker, P.M., Neale, B.M., Berger, B., et al. (2015). Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat Genet* 47, 284-290.
34. Gazal, S., Finucane, H.K., Furlotte, N.A., Loh, P.R., Palamara, P.F., Liu, X., Schoech, A., Bulik-

- Sullivan, B., Neale, B.M., Gusev, A., et al. (2017). Linkage disequilibrium-dependent architecture of human complex traits shows action of negative selection. *Nat Genet* 49, 1421-1427.
35. Fadista, J., Manning, A.K., Florez, J.C., and Groop, L. (2016). The (in)famous GWAS P-value threshold revisited and updated for low-frequency variants. *Eur J Hum Genet* 24, 1202-1205.
 36. Yang, J., Ferreira, T., Morris, A.P., Medland, S.E., Madden, P.A., Heath, A.C., Martin, N.G., Montgomery, G.W., Weedon, M.N., Loos, R.J., et al. (2012). Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet* 44, 369-375, S361-363.
 37. Genomes Project, C., Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M., Handsaker, R.E., Kang, H.M., Marth, G.T., and McVean, G.A. (2012). An integrated map of genetic variation from 1,092 human genomes. *Nature* 491, 56-65.
 38. Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014). The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res* 42, D1001-1006.
 39. Zheng, J., Erzurumluoglu, A.M., Elsworth, B.L., Kemp, J.P., Howe, L., Haycock, P.C., Hemani, G., Tansey, K., Laurin, C., Early, G., et al. (2017). LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* 33, 272-279.
 40. Pierce, B.L., Tong, L., Chen, L.S., Rahaman, R., Argos, M., Jasmine, F., Roy, S., Paul-Brutus, R., Westra, H.J., Franke, L., et al. (2014). Mediation analysis demonstrates that trans-eQTLs are often explained by cis-mediation: a genome-wide analysis among 1,800 South Asians. *PLoS Genet* 10, e1004818.
 41. Davis, J.R., Fresard, L., Knowles, D.A., Pala, M., Bustamante, C.D., Battle, A., and Montgomery, S.B. (2016). An Efficient Multiple-Testing Adjustment for eQTL Studies that Accounts for Linkage Disequilibrium between Variants. *Am J Hum Genet* 98, 216-224.
 42. Lappalainen, T., Sammeth, M., Friedlander, M.R., t Hoen, P.A., Monlong, J., Rivas, M.A., Gonzalez-Porta, M., Kurbatova, N., Griebel, T., Ferreira, P.G., et al. (2013). Transcriptome and genome sequencing uncovers functional variation in humans. *Nature* 501, 506-511.
 43. Montgomery, S.B., Sammeth, M., Gutierrez-Arcelus, M., Lach, R.P., Ingle, C., Nisbett, J., Guigo, R., and Dermitzakis, E.T. (2010). Transcriptome genetics using second generation sequencing in a Caucasian population. *Nature* 464, 773-777.
 44. Chang, X., and Wang, K. (2012). wANNOVAR: annotating genetic variants for personal genomes via the web. *J Med Genet* 49, 433-436.
 45. Loh, P.R., Bhatia, G., Gusev, A., Finucane, H.K., Bulik-Sullivan, B.K., Pollack, S.J., Schizophrenia Working Group of Psychiatric Genomics, C., de Candia, T.R., Lee, S.H., Wray, N.R., et al. (2015). Contrasting genetic architectures of schizophrenia and other complex diseases using fast variance-components analysis. *Nat Genet* 47, 1385-1392.
 46. Carey, G. (1988). Inference about genetic correlations. *Behav Genet* 18, 329-338.
 47. Thorburn, A.N., McKenzie, C.I., Shen, S., Stanley, D., Macia, L., Mason, L.J., Roberts, L.K., Wong, C.H., Shim, R., Robert, R., et al. (2015). Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. *Nature communications* 6, 7320.
 48. Joehanes, R., Just, A.C., Marioni, R.E., Pilling, L.C., Reynolds, L.M., Mandaviya, P.R., Guan, W., Xu, T., Elks, C.E., Aslibekyan, S., et al. (2016). Epigenetic Signatures of Cigarette Smoking. *Circ Cardiovasc Genet* 9, 436-447.
 49. Midodzi, W.K., Rowe, B.H., Majaesic, C.M., Saunders, L.D., and Senthilselvan, A. (2010). Early life factors associated with incidence of physician-diagnosed asthma in preschool children: results from the Canadian Early Childhood Development cohort study. *J Asthma* 47, 7-13.

50. Ferry, O.R., Duffy, D.L., and Ferreira, M.A. (2014). Early life environmental predictors of asthma age-of-onset. *Immun Inflamm Dis* 2, 141-151.
51. Scott, M., Roberts, G., Kurukulaaratchy, R.J., Matthews, S., Nove, A., and Arshad, S.H. (2012). Multifaceted allergen avoidance during infancy reduces asthma during childhood with the effect persisting until age 18 years. *Thorax* 67, 1046-1051.
52. Holt, P.G., and Sly, P.D. (2012). Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. *Nat Med* 18, 726-735.
53. de Marco, R., Pattaro, C., Locatelli, F., Svanes, C., and Group, E.S. (2004). Influence of early life exposures on incidence and remission of asthma throughout life. *J Allergy Clin Immunol* 113, 845-852.
54. Litonjua, A.A., Milton, D.K., Celedon, J.C., Ryan, L., Weiss, S.T., and Gold, D.R. (2002). A longitudinal analysis of wheezing in young children: the independent effects of early life exposure to house dust endotoxin, allergens, and pets. *J Allergy Clin Immunol* 110, 736-742.
55. Lee-Sarwar, K., and Litonjua, A.A. (2018). As You Eat It: Effects of Prenatal Nutrition on Asthma. *The journal of allergy and clinical immunology In practice* 6, 711-718.
56. Ghosh, R.E., Cullinan, P., Fishwick, D., Hoyle, J., Warburton, C.J., Strachan, D.P., Butland, B.K., and Jarvis, D. (2013). Asthma and occupation in the 1958 birth cohort. *Thorax* 68, 365-371.
57. Karjalainen, A., Martikainen, R., Karjalainen, J., Klaukka, T., and Kurppa, K. (2002). Excess incidence of asthma among Finnish cleaners employed in different industries. *Eur Respir J* 19, 90-95.
58. Brumpton, B., Langhammer, A., Romundstad, P., Chen, Y., and Mai, X.M. (2013). General and abdominal obesity and incident asthma in adults: the HUNT study. *Eur Respir J* 41, 323-329.
59. Pickrell, J.K., Berisa, T., Liu, J.Z., Segurel, L., Tung, J.Y., and Hinds, D.A. (2016). Detection and interpretation of shared genetic influences on 42 human traits. *Nat Genet* 48, 709-717.
60. MacArthur, J., Bowler, E., Cerezo, M., Gil, L., Hall, P., Hastings, E., Junkins, H., McMahon, A., Milano, A., Morales, J., et al. (2017). The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). *Nucleic Acids Res* 45, D896-D901.
61. Clingan, J.M., and Matloubian, M. (2013). B Cell-intrinsic TLR7 signaling is required for optimal B cell responses during chronic viral infection. *J Immunol* 191, 810-818.
62. Davidson, S., Kaiko, G., Loh, Z., Lalwani, A., Zhang, V., Spann, K., Foo, S.Y., Hansbro, N., Uematsu, S., Akira, S., et al. (2011). Plasmacytoid dendritic cells promote host defense against acute pneumovirus infection via the TLR7-MyD88-dependent signaling pathway. *J Immunol* 186, 5938-5948.
63. Cros, J., Cagnard, N., Woollard, K., Patey, N., Zhang, S.Y., Senechal, B., Puel, A., Biswas, S.K., Moshous, D., Picard, C., et al. (2010). Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. *Immunity* 33, 375-386.
64. Lu, L., Barbi, J., and Pan, F. (2017). The regulation of immune tolerance by FOXP3. *Nature reviews Immunology* 17, 703-717.
65. Gaynor, E.C., Mondesert, G., Grimme, S.J., Reed, S.I., Orlean, P., and Emr, S.D. (1999). MCD4 encodes a conserved endoplasmic reticulum membrane protein essential for glycosylphosphatidylinositol anchor synthesis in yeast. *Molecular biology of the cell* 10, 627-648.
66. Yadav, U., and Khan, M.A. (2018). Targeting the GPI biosynthetic pathway. *Pathog Glob Health* 112, 115-122.
67. Zhong, X., Malhotra, R., and Guidotti, G. (2003). ATP uptake in the Golgi and extracellular release require Mcd4 protein and the vacuolar H⁺-ATPase. *J Biol Chem* 278, 33436-33444.
68. Wain, L.V., Shrine, N., Miller, S., Jackson, V.E., Ntalla, I., Soler Artigas, M., Billington, C.K., Kheirallah, A.K., Allen, R., Cook, J.P., et al. (2015). Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. *The Lancet Respiratory medicine* 3, 769-781.

69. Wu, X., Briseno, C.G., Grajales-Reyes, G.E., Haldar, M., Iwata, A., Kretzer, N.M., Kc, W., Tussiwand, R., Higashi, Y., Murphy, T.L., et al. (2016). Transcription factor Zeb2 regulates commitment to plasmacytoid dendritic cell and monocyte fate. *Proc Natl Acad Sci U S A* 113, 14775-14780.
70. Scott, C.L., Soen, B., Martens, L., Skrypek, N., Saelens, W., Taminiau, J., Blancke, G., Van Isterdael, G., Huylebroeck, D., Haigh, J., et al. (2016). The transcription factor Zeb2 regulates development of conventional and plasmacytoid DCs by repressing Id2. *J Exp Med* 213, 897-911.
71. Omilusik, K.D., Best, J.A., Yu, B., Goossens, S., Weidemann, A., Nguyen, J.V., Seuntjens, E., Stryjewska, A., Zweier, C., Roychoudhuri, R., et al. (2015). Transcriptional repressor ZEB2 promotes terminal differentiation of CD8⁺ effector and memory T cell populations during infection. *J Exp Med* 212, 2027-2039.
72. Barbu, E.A., Zhang, J., Berenstein, E.H., Groves, J.R., Parks, L.M., and Siraganian, R.P. (2012). The transcription factor Zeb2 regulates signaling in mast cells. *J Immunol* 188, 6278-6286.
73. Alasoo, K., Rodrigues, J., Mukhopadhyay, S., Knights, A.J., Mann, A.L., Kundu, K., Consortium, H., Hale, C., Dougan, G., and Gaffney, D.J. (2018). Shared genetic effects on chromatin and gene expression indicate a role for enhancer priming in immune response. *Nat Genet* 50, 424-431.
74. Nedelec, Y., Sanz, J., Baharian, G., Szpiech, Z.A., Pacis, A., Dumaine, A., Grenier, J.C., Freiman, A., Sams, A.J., Hebert, S., et al. (2016). Genetic Ancestry and Natural Selection Drive Population Differences in Immune Responses to Pathogens. *Cell* 167, 657-669 e621.
75. Gunawardhana, L.P., Gibson, P.G., Simpson, J.L., Powell, H., and Baines, K.J. (2014). Activity and expression of histone acetylases and deacetylases in inflammatory phenotypes of asthma. *Clin Exp Allergy* 44, 47-57.
76. Zuccaro, L., Cox, A., Pray, C., Radford, K., Novakowski, K., Dorrington, M., Surette, M.G., Bowdish, D., and Nair, P. (2016). Histone deacetylase activity and recurrent bacterial bronchitis in severe eosinophilic asthma. *Allergy* 71, 571-575.
77. Ito, K., Ito, M., Elliott, W.M., Cosio, B., Caramori, G., Kon, O.M., Barczyk, A., Hayashi, S., Adcock, I.M., Hogg, J.C., et al. (2005). Decreased histone deacetylase activity in chronic obstructive pulmonary disease. *N Engl J Med* 352, 1967-1976.
78. Barneda-Zahonero, B., Roman-Gonzalez, L., Collazo, O., Rafati, H., Islam, A.B., Bussmann, L.H., di Tullio, A., De Andres, L., Graf, T., Lopez-Bigas, N., et al. (2013). HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages. *PLoS Genet* 9, e1003503.
79. Liu, Y., Helms, C., Liao, W., Zaba, L.C., Duan, S., Gardner, J., Wise, C., Miner, A., Malloy, M.J., Pullinger, C.R., et al. (2008). A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. *PLoS Genet* 4, e1000041.
80. Marquez, A., Vidal-Bralo, L., Rodriguez-Rodriguez, L., Gonzalez-Gay, M.A., Balsa, A., Gonzalez-Alvaro, I., Carreira, P., Ortego-Centeno, N., Ayala-Gutierrez, M.M., Garcia-Hernandez, F.J., et al. (2017). A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus. *Ann Rheum Dis* 76, 286-294.
81. Rymen, D., Winter, J., Van Hasselt, P.M., Jaeken, J., Kasapkara, C., Gokcay, G., Haijes, H., Goyens, P., Tokatli, A., Thiel, C., et al. (2015). Key features and clinical variability of COG6-CDG. *Mol Genet Metab* 116, 163-170.
82. Mazurek, J.M., Schleiff, P.L., and Henneberger, P.K. (2012). Is childhood asthma associated with educational level and longest-held occupation? *Am J Epidemiol* 175, 279-288.
83. Sturdy, P., Bremner, S., Harper, G., Mayhew, L., Eldridge, S., Eversley, J., Sheikh, A., Hunter, S., Boomla, K., Feder, G., et al. (2012). Impact of asthma on educational attainment in a socioeconomically deprived population: a study linking health, education and social care datasets. *PLoS One* 7, e43977.
84. Rohrmann, S., Steinbrecher, A., Linseisen, J., Hermann, S., May, A., Luan, J., Ekelund, U.,

- Overvad, K., Tjønneland, A., Halkjaer, J., et al. (2012). The association of education with long-term weight change in the EPIC-PANACEA cohort. *Eur J Clin Nutr* 66, 957-963.
85. Granell, R., Henderson, A.J., Evans, D.M., Smith, G.D., Ness, A.R., Lewis, S., Palmer, T.M., and Sterne, J.A. (2014). Effects of BMI, fat mass, and lean mass on asthma in childhood: a Mendelian randomization study. *PLoS medicine* 11, e1001669.
 86. Minelli, C., van der Plaat, D.A., Leynaert, B., Granell, R., Amaral, A.F.S., Pereira, M., Mahmoud, O., Potts, J., Sheehan, N.A., Bowden, J., et al. (2018). Age at puberty and risk of asthma: A Mendelian randomisation study. *PLoS medicine* 15, e1002634.
 87. Chen, Y.C., Fan, H.Y., Huang, Y.T., Huang, S.Y., Liou, T.H., and Lee, Y.L. (2018). Causal relationships between adiposity and childhood asthma: bi-directional Mendelian Randomization analysis. *Int J Obes (Lond)*.
 88. Skaaby, T., Taylor, A.E., Jacobsen, R.K., Paternoster, L., Thuesen, B.H., Ahluwalia, T.S., Larsen, S.C., Zhou, A., Wong, A., Gabrielsen, M.E., et al. (2017). Investigating the causal effect of smoking on hay fever and asthma: a Mendelian randomization meta-analysis in the CARTA consortium. *Scientific reports* 7, 2224.
 89. Skaaby, T., Taylor, A.E., Thuesen, B.H., Jacobsen, R.K., Friedrich, N., Mollehave, L.T., Hansen, S., Larsen, S.C., Volker, U., Nauck, M., et al. (2018). Estimating the causal effect of body mass index on hay fever, asthma and lung function using Mendelian randomization. *Allergy* 73, 153-164.

FIGURE TITLES AND LEGENDS

Figure 1. Summary of association results from the GWAS of COA and AOA in the UK Biobank study. The middle panel shows the Manhattan plots (left for childhood-onset asthma [COA], based on 13,962 cases and 300,671 controls; right for adult-onset asthma [AOA], based on 26,582 cases and 300,671 controls) with variants associated with disease risk at a $P < 3 \times 10^{-8}$ (red vertical line) highlighted in red; associations with $P < 10^{-21}$ are shown with $P = 10^{-21}$. For COA, sentinel variants that were in low LD ($r^2 < 0.05$) with previous reported associations for allergic disease are shown with a black circle (25 out of 123 in total), with the green line pointing to additional information on the adjacent left panel. Specifically, the left panel indicates: (1) if the association with COA replicated in the independent 23andMe study ($P < 0.05$ and same direction of effect; “1”=yes, “0”=no, “NA”=results not available); (2) the minor allele frequency (MAF; in %) in the case group, with the square indicating whether the risk allele occurred at a significantly greater (in black; $P < 0.05$ and $OR > 1$ in the COA vs. AOA case-case analysis, *i.e.* stronger risk factor for COA), similar (in grey; $P \geq 0.05$ in the case-case analysis, *i.e.* similar association with COA and AOA) or lower (in white; $P < 0.05$ and $OR < 1$ in the case-case analysis; *i.e.* stronger risk factor for AOA) frequency in COA when compared to AOA cases; and (3) the location of the sentinel risk variant relative to the nearest genes (in black font) or, for variants with an association that replicated in the 23andMe study and with a target gene prediction, the likely target gene(s) based on LD ($r^2 > 0.8$) with non-synonymous or sentinel eQTL (in blue font). The location of the sentinel risk variant (when shown) is indicated by “gene1--[]--gene2”, the two closest genes (upstream and downstream), when the variant was intergenic; the distance to each gene is proportional to the number of “-“ shown. Otherwise, when the risk variant was located within a gene, the respective gene name is shown between square brackets (*i.e.* [gene]). The right panel shows the same information for all 56 sentinel variants associated with AOA, which were grouped into those that (1) were in LD ($r^2 > 0.05$) with sentinel variants identified in the COA GWAS (37 variants; highlighted

by a black line); (2) were in LD ($r^2 > 0.05$) with previous reported associations for allergic disease (8 variants; highlighted by an orange line); or (3) were not in LD ($r^2 < 0.05$) with sentinel variants for COA, nor with previous reported associations for allergic disease (11 variants; highlighted by a green line).

Figure 2. Association between sentinel variants and risk of COA and AOA. The two panels (A and B) respectively show results for COA and AOA sentinel SNPs identified in the UK Biobank GWAS and that subsequently validated in the 23andMe replication study. The x-axis shows SNP effects (odds ratio; “OR”) estimated in the COA vs. control meta-analysis of the UK Biobank and 23andMe, while the y-axis shows the effect in the AOA vs. control meta-analysis of the same two studies. In panel A, variants for which the odds ratio in the AOA vs. control analysis was < 1.005 are highlighted in red, with their genomic context also highlighted. Similarly, in panel B, variants in red had an odds ratio < 1.005 in the COA vs. controls analysis. To help interpret the correlation in odds ratios between the two disease subtypes, regression lines with increasing beta coefficients (“b”, from 0.1 to 1) are shown in blue.

TABLES

Table 1. Liability scale SNP-based heritability (diagonal) of, and genetic correlation (lower diagonal) between, childhood-onset asthma (COA) and adult-onset asthma (AOA) in the UK Biobank study.

	COA (onset: 0-19)	yAOA (onset: 20-39)	oAOA (onset: 40-60)	AOA (onset: 20-60)
	13,962 vs 433,306	11,709 vs 435,559	14,873 vs 432,395	26,582 vs 420,686
COA	0.256 (0.007)	-	-	-
yAOA	0.831 (0.032)	0.098 (0.006)	-	-
oAOA	0.469 (0.031)	0.856 (0.050)	0.078 (0.005)	-
AOA	0.667 (0.023)	-	-	0.106 (0.004)

Standard error of the heritability estimate is shown in brackets.

1 **Table 2.** Independent SNP associations with risk of childhood-onset asthma (COA) discovered in the UK Biobank study (13,962 cases vs. 300,671
2 controls) and validated in the 23andMe study (31,759 cases vs. 214,890 controls).

Chr	Bp	Sentinel SNP	Context	A1	Discovery (UK Biobank)				Replication (23andMe)			Meta-analysis				
					OR	SE	P-value	A1 freq	OR	SE	P-value	OR	SE	P-value		
Sentinel SNPs that represent novel associations for allergic disease																
1	9356676	rs67551275	[SPSB1]	T	1.071	0.012	1.3E-08	0.53		1.067	0.010	5.9E-11		1.069	0.008	3.8E-18
1	172715702	rs78037977	FASLG-[]--TNFSF18	A	1.116	0.018	1.4E-09	0.88		1.066	0.015	1.6E-05		1.086	0.011	6.2E-13
1	213056427	rs12750027	[FLVCR1]	A	1.150	0.024	3.9E-09	0.07		1.075	0.022	1.4E-03		1.109	0.016	2.6E-10
2	224664050	rs6755248	[AP1S3]	G	1.070	0.012	1.6E-08	0.41		1.046	0.009	1.3E-06		1.055	0.007	3.2E-13
2	228670437	rs10187276	SLC19A3-[]-CCL20	T	1.116	0.014	7.0E-16	0.25		1.059	0.011	6.2E-08		1.079	0.009	1.5E-19
3	127912846	rs11412402	[EEFSEC]	D	1.073	0.012	3.2E-09	0.47		1.047	0.009	4.9E-07		1.057	0.007	3.9E-14
3	176852038	rs7626218	[TBL1XR1]	A	1.083	0.012	3.1E-11	0.60		1.031	0.009	1.5E-03		1.051	0.007	3.6E-11
6	409119	rs9391997	[IRF4]	G	1.077	0.012	3.1E-10	0.53		1.038	0.009	5.9E-05		1.052	0.007	3.8E-12
7	22780322	rs6954667	IL6-[]-TOMM7	A	1.074	0.013	2.6E-08	0.31		1.028	0.010	6.0E-03		1.045	0.008	3.0E-08
8	120063542	rs2450083	TNFRSF11B-[]-COLEC10	C	1.070	0.012	1.1E-08	0.50		1.037	0.009	1.2E-04		1.049	0.007	7.8E-11
9	23585839	rs274943	DMRTA1---[]--ELAVL2	T	1.080	0.012	9.1E-11	0.52		1.051	0.009	6.8E-08		1.062	0.007	2.6E-16
10	6093139	rs12722502	[IL2RA]	C	1.326	0.044	2.0E-10	0.98		1.235	0.053	4.3E-05		1.288	0.034	6.8E-14
10	6621773	rs943451	[PRKCQ]	T	1.105	0.013	7.5E-15	0.31		1.041	0.010	4.7E-05		1.063	0.008	3.5E-15
10	94384514	rs113092121	[KIF11]	I	1.092	0.012	1.8E-13	0.56		1.058	0.009	1.8E-09		1.070	0.007	2.5E-20
11	10664033	rs2052690	[MRV1]	T	1.077	0.013	1.5E-08	0.29		1.043	0.010	3.2E-05		1.056	0.008	1.1E-11
11	36365253	rs10836538	[PRR5L]	G	1.083	0.012	1.2E-10	0.65		1.040	0.010	5.4E-05		1.057	0.007	2.7E-13
12	55368291	rs62623446	[TESPA1]	T	1.138	0.023	1.7E-08	0.07		1.103	0.021	6.2E-06		1.119	0.016	8.0E-13
13	99974492	rs1887704	[UBAC2]	G	1.102	0.013	1.4E-14	0.68		1.059	0.010	4.8E-09		1.075	0.008	4.7E-20
16	27349168	rs3785356	[IL4R]	T	1.116	0.013	2.7E-17	0.29		1.073	0.010	2.5E-12		1.089	0.008	8.5E-27
16	50745926	rs2066844	[NOD2]	T	1.172	0.028	1.5E-08	0.05		1.086	0.022	2.5E-04		1.119	0.017	1.3E-10
18	48647640	rs1893380	SMAD4-[]-MEX3C	C	1.083	0.012	5.2E-11	0.38		1.039	0.009	5.7E-05		1.055	0.007	3.6E-13
18	51816408	rs12965763	[POLI]	A	1.100	0.014	2.3E-11	0.22		1.034	0.011	2.3E-03		1.059	0.009	4.3E-11
19	1152656	rs892225	[SBNO2]	G	1.080	0.012	3.4E-10	0.38		1.040	0.010	9.7E-05		1.057	0.008	1.1E-12
23	13023741	rs850637	TMSB4X-[]-FAM9C	G	1.064	0.010	2.2E-10	0.56		1.036	0.008	3.3E-06		1.046	0.006	8.3E-14
23	49139787	rs5953283	[PPP1R3F]	A	1.064	0.010	3.1E-10	0.40		1.024	0.008	2.2E-03		1.038	0.006	5.6E-10
Sentinel SNPs in LD (r2>0.05) with variants previously reported to associate with allergic disease																
1	151801680	rs4845604	[RORC]	G	1.140	0.017	9.5E-15	0.86		1.062	0.014	9.2E-06		1.092	0.011	1.5E-16
1	152179152	rs12123821	RPTN-[]-HRNR	T	1.523	0.028	4.0E-51	0.05		1.163	0.025	1.1E-09		1.307	0.018	7.6E-48

1	161185058	rs2070901	NDUFS2-[]-FCER1G	T	1.093	0.013	2.4E-11	0.27	1.105	0.010	4.2E-22	1.100	0.008	2.8E-32
1	167436270	rs1617333	[CD247]	A	1.098	0.012	9.9E-15	0.60	1.061	0.009	4.3E-10	1.075	0.007	2.5E-22
1	173131493	rs10158467	TNFSF18-[]-TNFSF4	G	1.116	0.013	6.3E-17	0.28	1.079	0.010	5.0E-14	1.093	0.008	8.3E-29
1	203093201	rs12023876	MYOG-[]-ADORA1	G	1.080	0.012	7.8E-10	0.67	1.071	0.010	4.3E-12	1.074	0.008	4.9E-21
2	8459404	rs3856439	[LINC00299]	C	1.113	0.012	6.0E-18	0.66	1.070	0.010	7.0E-12	1.087	0.008	6.2E-28
2	102798245	rs74180212	IL1R1-[]-IL1RL2	G	1.123	0.012	1.1E-20	0.44	1.087	0.010	1.6E-17	1.101	0.008	5.3E-37
2	102882352	rs78545931	IL1RL2-[]-IL18R1	A	1.408	0.033	4.2E-25	0.98	1.391	0.027	5.9E-37	1.398	0.021	8.8E-59
2	102936159	rs72823641	[IL18R1]	T	1.341	0.017	6.9E-68	0.86	1.281	0.014	5.4E-75	1.305	0.011	2E-136
2	102966906	rs1861245	[IL1RL1]	C	1.194	0.013	9.3E-45	0.66	1.124	0.010	3.9E-32	1.150	0.008	2.3E-69
2	112268732	rs143326447	BCL2L11-[]-ANAPC1	C	1.108	0.018	1.8E-08	0.12	1.047	0.015	2.0E-03	1.071	0.011	1.8E-09
2	242698640	rs34290285	[D2HGDH]	G	1.198	0.013	3.3E-41	0.74	1.142	0.012	5.5E-29	1.168	0.009	4.2E-69
3	33047662	rs35570272	[GLB1]	T	1.106	0.012	7.8E-17	0.39	1.029	0.009	2.3E-03	1.057	0.007	4.1E-14
3	121716171	rs1806656	[ILDR1]	C	1.082	0.013	6.3E-10	0.68	1.036	0.010	6.4E-04	1.053	0.008	1.2E-10
3	141150026	rs7625643	[ZBTB38]	G	1.070	0.012	2.1E-08	0.44	1.029	0.009	2.7E-03	1.044	0.007	4.9E-09
3	188128979	rs9860547	[LPP]	A	1.135	0.012	1.9E-26	0.45	1.087	0.009	1.5E-19	1.105	0.007	3.6E-42
3	188401138	rs55661102	[LPP]	A	1.101	0.016	9.0E-10	0.83	1.093	0.013	2.4E-12	1.096	0.010	4.1E-20
4	38798648	rs5743618	[TLR1]	C	1.210	0.014	2.1E-43	0.76	1.141	0.011	1.7E-36	1.165	0.008	3.2E-74
4	123353432	rs17454584	ADAD1-[]-IL2	G	1.126	0.014	1.5E-16	0.21	1.106	0.011	2.1E-20	1.114	0.009	5.9E-36
5	14610309	rs16903574	[FAM105A]	G	1.191	0.023	2.1E-14	0.07	1.122	0.017	7.9E-12	1.145	0.013	1.0E-23
5	110158844	rs7734635	SLC25A46-[]-TSLP	G	1.176	0.016	3.7E-23	0.15	1.084	0.012	1.8E-11	1.116	0.009	1.9E-30
5	110401872	rs1837253	SLC25A46-[]-TSLP	C	1.182	0.013	1.2E-35	0.74	1.189	0.011	1.6E-59	1.186	0.008	7.1E-94
5	110470137	rs6594499	WDR36-[]-CAMK4	C	1.147	0.012	3.3E-31	0.51	1.126	0.009	5.4E-38	1.134	0.007	3.9E-66
5	131799626	rs3749833	[C5orf56]	C	1.109	0.013	1.3E-14	0.26	1.057	0.011	2.2E-07	1.077	0.008	1.2E-19
5	131916940	rs2299012	[RAD50]	C	1.191	0.015	1.9E-31	0.19	1.115	0.011	7.6E-23	1.141	0.009	1.0E-49
5	132105698	rs113010607	[SEPT8]	C	1.172	0.022	4.1E-13	0.07	1.101	0.017	6.1E-09	1.126	0.013	2.0E-19
5	141533062	rs449454	[NDFIP1]	G	1.084	0.012	3.0E-11	0.62	1.070	0.010	1.1E-12	1.076	0.007	2.0E-22
6	31303324	rs114444221	[HLA-B]	A	1.231	0.027	2.3E-14	0.97	1.095	0.017	1.2E-07	1.133	0.015	9.0E-18
6	33033824	rs111789468	[HLA-DPA1]	T	1.222	0.030	1.3E-11	0.03	1.069	0.013	4.1E-07	1.092	0.012	2.2E-13
6	33099538	rs3116989	HLA-DPB2-[]-COL11A2	G	1.151	0.017	5.3E-16	0.87	1.060	0.014	3.2E-05	1.096	0.011	2.6E-17
6	90976609	rs62408233	[BACH2]	G	1.113	0.012	2.9E-18	0.64	1.096	0.010	3.3E-21	1.103	0.008	2.8E-38
6	106667535	rs9372120	[ATG5]	G	1.106	0.015	5.5E-12	0.21	1.078	0.011	4.2E-11	1.088	0.009	8.8E-21
6	128293562	rs55743914	[PTPRK]	T	1.105	0.014	4.8E-13	0.24	1.051	0.011	5.0E-06	1.071	0.009	1.5E-15
6	138002175	rs6927172	OLIG3-[]-LOC100130476	C	1.090	0.014	1.4E-09	0.78	1.051	0.011	1.1E-05	1.067	0.009	3.3E-13
7	20423923	rs149317277	[ITGB8]	D	1.087	0.012	6.6E-12	0.61	1.050	0.009	3.0E-07	1.064	0.007	8.4E-17
7	20544209	rs12531500	ITGB8-[]-ABCB5	A	1.103	0.012	1.8E-16	0.57	1.056	0.009	5.3E-09	1.073	0.007	6.7E-22
7	28156606	rs4722758	[JAZF1]	G	1.126	0.015	6.2E-16	0.20	1.090	0.011	6.1E-15	1.103	0.009	2.8E-28
8	81294702	rs2221641	MIR5708-[]-ZBTB10	C	1.112	0.012	2.4E-18	0.38	1.074	0.009	2.2E-14	1.088	0.007	1.8E-30

8	128777719	rs13277355	POU5F1B--[]-MYC	A	1.103	0.013	1.4E-13	0.27	1.072	0.010	7.1E-12	1.084	0.008	9.5E-24
9	6081804	rs340934	RANBP6-[]-IL33	T	1.208	0.015	1.6E-36	0.81	1.142	0.012	8.7E-30	1.167	0.009	3.1E-62
9	6213468	rs7848215	RANBP6--[]-IL33	T	1.255	0.014	4.1E-63	0.25	1.181	0.010	1.3E-59	1.206	0.008	5E-115
10	8606014	rs17144046	GATA3--[]---SFTA1P	G	1.102	0.013	7.0E-13	0.28	1.044	0.010	3.3E-05	1.066	0.008	2.9E-15
10	9049253	rs12413578	GATA3---[]---SFTA1P	C	1.204	0.019	1.7E-22	0.89	1.160	0.016	7.7E-21	1.178	0.012	9.1E-41
10	9064716	rs1612986	GATA3---[]---SFTA1P	C	1.168	0.015	4.5E-24	0.18	1.110	0.012	8.3E-19	1.131	0.009	8.3E-41
10	64391375	rs10995245	[ZNF365]	A	1.073	0.012	1.3E-08	0.35	1.033	0.010	9.2E-04	1.048	0.007	3.6E-10
11	65551957	rs479844	AP5B1-[]-OVOL1	G	1.116	0.012	1.4E-20	0.55	1.052	0.009	3.9E-08	1.075	0.007	3.2E-23
11	76299431	rs55646091	WNT11--[]-LRRC32	A	1.513	0.028	3.9E-50	0.05	1.283	0.021	8.5E-30	1.364	0.017	5.9E-74
11	76299649	rs11236797	WNT11--[]-LRRC32	A	1.214	0.012	2.4E-60	0.45	1.132	0.009	1.0E-41	1.162	0.007	1E-93
11	118743286	rs12365699	DDX6-[]-CXCR5	G	1.141	0.016	6.1E-17	0.83	1.106	0.013	4.2E-16	1.119	0.010	4.3E-30
11	128172836	rs140522418	KIRREL3-AS3---[]--ETS1	D	1.095	0.015	4.8E-09	0.82	1.039	0.012	1.9E-03	1.062	0.010	4.3E-10
12	56389293	rs705700	[RAB5B]	C	1.108	0.012	8.1E-18	0.42	1.060	0.009	4.3E-10	1.078	0.007	2.5E-24
12	57509102	rs3122929	[STAT6]	T	1.141	0.012	7.6E-28	0.40	1.067	0.009	5.7E-12	1.095	0.007	2.4E-34
12	112059557	rs11065979	ATXN2-[]-BRAP	C	1.085	0.012	6.5E-12	0.56	1.054	0.009	1.3E-08	1.066	0.007	4.8E-18
12	121365431	rs188074962	SPPL3-[]-HNF1A-AS1	G	1.112	0.012	8.8E-18	0.35	1.048	0.010	1.9E-06	1.073	0.008	1.6E-20
12	123635096	rs1716183	[PITPNM2]	C	1.098	0.016	2.2E-09	0.83	1.049	0.013	1.2E-04	1.067	0.010	3.5E-11
14	68754695	rs1885013	[RAD51B]	G	1.098	0.013	1.0E-12	0.28	1.078	0.010	4.4E-14	1.085	0.008	2.9E-25
14	103244070	rs71421264	[TRAF3]	G	1.081	0.012	1.0E-10	0.59	1.032	0.009	7.2E-04	1.050	0.007	2.8E-11
15	41787585	rs1655558	[ITPKA]	G	1.087	0.012	2.8E-12	0.55	1.056	0.010	1.7E-08	1.068	0.007	2.2E-18
15	61069988	rs11071559	[RORA]	C	1.185	0.017	1.9E-22	0.87	1.121	0.014	2.5E-17	1.145	0.011	2.0E-37
15	67441750	rs72743461	[SMAD3]	A	1.196	0.014	1.7E-37	0.23	1.127	0.011	3.8E-29	1.152	0.009	6.4E-63
15	67475764	rs34445740	[SMAD3]	D	1.111	0.013	4.7E-16	0.70	1.055	0.010	1.8E-07	1.076	0.008	7.7E-20
16	11219041	rs12935657	[CLEC16A]	G	1.154	0.014	6.1E-26	0.75	1.122	0.011	1.3E-27	1.133	0.009	1.0E-49
17	38061439	rs4795399	[GSDMB]	T	1.303	0.012	3E-111	0.53	1.280	0.009	2E-155	1.289	0.007	1E-257
17	38064971	rs117097909	[GSDMB]	A	1.355	0.026	1.5E-31	0.05	1.247	0.022	3.7E-22	1.292	0.017	1.6E-51
17	38755021	rs9893132	CCR7-[]-SMARCE1	G	1.095	0.012	1.4E-13	0.64	1.047	0.010	1.7E-06	1.065	0.007	3.0E-17
17	38764524	rs112401631	CCR7-[]-SMARCE1	A	1.354	0.043	1.6E-12	0.02	1.265	0.044	1.9E-07	1.310	0.031	2.1E-18
17	43457886	rs9895436	MAP3K14-[]-ARHGAP27	A	1.089	0.012	1.8E-12	0.40	1.058	0.009	1.4E-09	1.070	0.007	5.9E-20
17	47448346	rs12952581	ZNF652-[]-PHB	A	1.094	0.012	2.4E-13	0.36	1.069	0.010	3.2E-12	1.078	0.007	4.4E-24
18	60009814	rs4574025	[TNFRSF11A]	T	1.092	0.012	1.3E-13	0.53	1.036	0.010	2.2E-04	1.058	0.007	8.0E-14
18	61442619	rs12964116	[SERPINB7]	G	1.293	0.031	3.0E-16	0.04	1.143	0.041	1.1E-03	1.236	0.025	8.4E-18
19	8785744	rs2918302	ADAMTS10--[]-ACTL9	A	1.107	0.016	5.8E-10	0.15	1.037	0.013	3.5E-03	1.064	0.010	4.8E-10
19	33726578	rs117710327	SLC7A10-[]-CEBPA	C	1.205	0.024	4.7E-15	0.94	1.189	0.021	1.2E-16	1.196	0.016	2.8E-29

3

4

Table 3. Independent SNP associations with risk of adult-onset asthma (AOA) discovered in the UK Biobank study (26,582 cases vs. 300,671 controls) and validated in the 23andMe study (16,297 cases vs. 217,711 controls).

Chr	Bp	Sentinel SNP	Context	A1	Discovery (UK Biobank)					Replication (23andMe)				Meta-analysis		
					OR	SE	P-value	A1 freq		OR	SE	P-value		OR	SE	P-value
Sentinel SNPs that represent novel associations for allergic disease																
1	198640488	rs17668708	[PTPRC]	C	1.096	0.014	2.4E-11	0.90		1.069	0.020	6.9E-04		1.087	0.011	3.0E-13
2	146145018	rs2381712	TEX41--[]---PABPC1P2	G	1.056	0.008	9.5E-11	0.52		1.057	0.012	4.9E-06		1.056	0.007	2.5E-16
10	6093139	rs12722502	[IL2RA]	C	1.237	0.032	1.9E-11	0.98		1.156	0.067	2.8E-02		1.222	0.029	4.3E-12
13	40319954	rs28635831	[COG6]	A	1.051	0.009	1.7E-08	0.65		1.030	0.013	1.9E-02		1.044	0.007	4.3E-09
13	100070457	rs4771332	MIR548AN--[]-TM9SF2	C	1.061	0.009	9.8E-11	0.69		1.035	0.013	9.5E-03		1.053	0.007	5.5E-12
16	27369502	rs3024655	[IL4R]	G	1.133	0.018	1.1E-12	0.94		1.051	0.025	4.9E-02		1.105	0.015	1.1E-11
Sentinel SNPs in LD (r2>0.05) with variants previously reported to associate with allergic disease																
1	167420299	rs2056625	[CD247]	G	1.060	0.009	5.6E-12	0.59		1.027	0.012	2.9E-02		1.048	0.007	7.6E-11
2	102892339	rs60227565	IL1RL2--[]-IL18R1	G	1.146	0.012	1.8E-28	0.87		1.082	0.018	7.7E-06		1.125	0.010	1.4E-32
2	102926362	rs12470864	IL1RL2--[]-IL18R1	A	1.104	0.009	2.3E-30	0.38		1.061	0.012	1.5E-06		1.089	0.007	1.1E-31
2	242698640	rs34290285	[D2HGDH]	G	1.100	0.010	2.9E-23	0.74		1.091	0.016	1.8E-08		1.097	0.008	2.2E-28
3	33083985	rs4491851	[GLB1]	A	1.056	0.008	1.0E-10	0.53		1.035	0.012	4.0E-03		1.050	0.007	3.7E-13
4	123359569	rs62322662	ADAD1--[]-IL2	G	1.096	0.016	8.1E-09	0.08		1.059	0.023	1.2E-02		1.084	0.013	7.9E-10
5	35881376	rs11742240	IL7R--[]-CAPSL	G	1.063	0.009	6.1E-11	0.72		1.045	0.014	1.1E-03		1.058	0.007	9.1E-14
5	110161473	rs540485182	SLC25A46--[]--TSLP	I	1.090	0.012	1.7E-13	0.15		1.058	0.016	4.2E-04		1.078	0.010	3.8E-15
5	110401872	rs1837253	SLC25A46--[]-TSLP	C	1.084	0.010	2.9E-17	0.74		1.055	0.014	1.1E-04		1.074	0.008	1.4E-18
5	110408002	rs1898671	[TSLP]	T	1.082	0.009	5.5E-19	0.35		1.060	0.013	4.9E-06		1.074	0.007	1.4E-22
5	131787137	rs6866614	[IRF1]	G	1.075	0.009	2.0E-17	0.57		1.074	0.012	6.9E-09		1.075	0.007	4.4E-23
5	141518940	rs10699671	[NDFIP1]	I	1.051	0.009	9.9E-09	0.61		1.055	0.012	1.6E-05		1.052	0.007	2.4E-12
6	90985198	rs58521088	[BACH2]	A	1.074	0.009	5.1E-16	0.64		1.026	0.013	4.6E-02		1.058	0.007	2.5E-14
8	81302012	rs35204956	MIR5708--[]-ZBTB10	D	1.063	0.009	2.2E-12	0.39		1.057	0.012	6.9E-06		1.061	0.007	4.0E-16
9	6047765	rs62557312	RANBP6--[]-IL33	C	1.104	0.011	2.0E-19	0.82		1.049	0.016	2.1E-03		1.085	0.009	8.0E-20
9	6209697	rs992969	RANBP6--[]-IL33	A	1.115	0.010	2.4E-29	0.25		1.059	0.014	2.8E-05		1.095	0.008	2.0E-29
10	8777640	rs10795672	GATA3---[]---SFTA1P	A	1.061	0.009	5.4E-12	0.47		1.040	0.013	2.5E-03		1.054	0.007	1.0E-12
10	9054340	rs1775554	GATA3---[]---SFTA1P	A	1.109	0.008	3.0E-34	0.57		1.085	0.012	4.2E-11		1.102	0.007	3.1E-47
11	76293726	rs7936312	WNT11--[]-LRRC32	T	1.089	0.008	6.1E-24	0.47		1.062	0.012	5.8E-07		1.081	0.007	2.5E-31
12	48186563	rs2544026	[HDAC7]	T	1.060	0.010	1.7E-09	0.75		1.066	0.014	6.2E-06		1.062	0.008	2.0E-13
12	56449435	rs7302200	RPS26-[]-ERBB3	A	1.071	0.009	1.8E-14	0.34		1.036	0.013	5.3E-03		1.059	0.007	4.4E-15

12	57489709	rs1059513	[STAT6]	T		1.119	0.013	5.3E-17	0.89		1.072	0.020	3.7E-04		1.105	0.011	4.7E-20
15	61049569	rs7183955	[RORA]	A		1.070	0.011	4.3E-10	0.81		1.049	0.015	1.6E-03		1.063	0.009	8.3E-12
15	67441750	rs72743461	[SMAD3]	A		1.097	0.010	1.7E-20	0.23		1.067	0.014	3.8E-06		1.087	0.008	1.4E-24
16	11213021	rs35441874	[CLEC16A]	T		1.081	0.010	1.1E-15	0.75		1.067	0.014	2.5E-06		1.076	0.008	1.2E-19
17	47465743	rs10667251	ZNF652-[]-PHB	D		1.049	0.009	2.2E-08	0.58		1.033	0.012	9.0E-03		1.043	0.007	5.4E-09
19	33726578	rs117710327	SLC7A10-[]-CEBPA	C		1.152	0.017	9.3E-17	0.94		1.089	0.027	1.5E-03		1.134	0.014	2.8E-18
21	36464631	rs11088309	[RUNX1]	G		1.088	0.012	2.4E-12	0.14		1.035	0.017	4.7E-02		1.070	0.010	5.2E-12

7

8

9 **Table 4.** Genes with a sentinel eQTL and/or non-synonymous SNP in LD ($r^2 \geq 0.8$) with sentinel asthma risk variants identified in the GWAS of COA or
10 AOA.

Chr	Bp	Sentinel SNP	Novel association	Context	LD between sentinel eQTL/non-synonymous SNP and sentinel GWAS SNP*	
					$r^2 \geq 0.95$	$0.8 \leq r^2 < 0.95$
Sentinel SNPs identified in the GWAS of COA						
1	151801680	rs4845604	No	[RORC]	RORC,TUFT1	-
1	161185058	rs2070901	No	NDUFS2-[]-FCER1G	F11R,FCER1G,TOMM40L,USF1	-
1	167436270	rs1617333	No	[CD247]	CD247	-
1	173131493	rs10158467	No	TNFSF18--[]-TNFSF4	TNFSF4	-
1	203093201	rs12023876	No	MYOG-[]-ADORA1	ADORA1,CHIT1,MYBPH,PPFIA4,RP11-335O13.7	-
1	213056427	rs12750027	Yes	[FLVCR1]	-	FLVCR1,FLVCR1-AS1
2	102882352	rs78545931	No	IL1RL2-[]-IL18R1	IL18RAP,IL1RL1	MFSD9
2	102936159	rs72823641	No	[IL18R1]	MFSD9	-
2	102966906	rs1861245	No	[IL1RL1]	-	AC007278.3,IL18R1,IL1RL1
2	228670437	rs10187276	Yes	SLC19A3-[]-CCL20	CCL20	-
2	242698640	rs34290285	No	[D2HGDH]	PDCD1	-
3	141150026	rs7625643	No	[ZBTB38]	-	ZBTB38
3	188128979	rs9860547	No	[LPP]	BCL6	-
4	38798648	rs5743618	No	[TLR1]	TLR1	-
4	123353432	rs17454584	No	ADAD1-[]-IL2	KIAA1109	-
5	14610309	rs16903574	No	[FAM105A]	FAM105A	-
5	110470137	rs6594499	No	WDR36-[]-CAMK4	-	CTC-551A13.2,TSLP,WDR36
5	131799626	rs3749833	No	[C5orf56]	C5orf56,SLC22A4	-
5	131916940	rs2299012	No	[RAD50]	SLC22A5	-
5	141533062	rs449454	No	[NDFIP1]	NDFIP1	-
6	31303324	rs114444221	No	[HLA-B]	-	HLA-C,NOTCH4
6	33033824	rs111789468	No	[HLA-DPA1]	HLA-DPA1	HLA-DPB1,HLA-DQB1,TAPBP
7	20423923	rs149317277	No	[ITGB8]	-	ITGB8
7	28156606	rs4722758	No	[JAZF1]	JAZF1	-
10	6093139	rs12722502	Yes	[IL2RA]	IL2RA	-
10	6621773	rs943451	Yes	[PRKCQ]	PRKCQ	-
10	94384514	rs113092121	Yes	[KIF11]	-	EIF2S2P3,HHEX,KIF11

11	10664033	rs2052690	Yes	[MRV1]	-	<i>RNF141</i>
11	36365253	rs10836538	Yes	[PRR5L]	<i>PRR5L</i>	-
11	65551957	rs479844	No	AP5B1-[-OVOL1	<i>OVOL1</i>	<i>EFEMP2,SNX32</i>
11	76299649	rs11236797	No	WNT11-[-LRRC32	<i>LRRC32</i>	-
11	128172836	rs140522418	No	KIRREL3-AS3---[-ETS1	-	<i>ETS1</i>
12	55368291	rs62623446	Yes	[TESPA1]	<i>TESPA1</i>	-
12	56389293	rs705700	No	[RAB5B]	<i>RPS26,SUOX</i>	-
12	112059557	rs11065979	No	ATXN2-[-BRAP	<i>TCTN1,TRAFFD1</i>	<i>SH2B3</i>
12	121365431	rs188074962	No	SPPL3-[-HNF1A-AS1	<i>SPPL3</i>	-
13	99974492	rs1887704	Yes	[UBAC2]	-	<i>GPR183,UBAC2</i>
14	103244070	rs71421264	No	[TRAF3]	<i>TRAF3</i>	-
15	41787585	rs1655558	No	[ITPKA]	-	<i>D-JC17,ITPKA,RTF1,ZFYVE19</i>
15	61069988	rs11071559	No	[RORA]	-	<i>RP11-554D20.1</i>
15	67441750	rs72743461	No	[SMAD3]	<i>AAGAB</i>	-
15	67475764	rs34445740	No	[SMAD3]	<i>SMAD3</i>	-
16	11219041	rs12935657	No	[CLEC16A]	-	<i>SOCS1</i>
16	27349168	rs3785356	Yes	[IL4R]	<i>NSMCE1</i>	<i>IL4R</i>
16	50745926	rs2066844	Yes	[NOD2]	<i>NOD2</i>	-
17	38061439	rs4795399	No	[GSDMB]	<i>GSDMB,ORMDL3</i>	<i>GSDMA,IKZF3,RP11-94L15.2,ZPBP2</i>
17	38755021	rs9893132	No	CCR7-[-SMARCE1	<i>SMARCE1</i>	-
17	43457886	rs9895436	No	MAP3K14-[-ARHGAP27	<i>CRHR1,CRHR1-IT1,DND1P1,LRRC37A4P,RP11-105N13.4</i>	-
17	47448346	rs12952581	No	ZNF652-[-PHB	<i>GNGT2</i>	-
18	48647640	rs1893380	Yes	SMAD4-[-MEX3C	<i>RP11-729L2.2,SMAD4</i>	-
18	60009814	rs4574025	No	[TNFRSF11A]	<i>PIGN</i>	-
18	61442619	rs12964116	No	[SERPINB7]	<i>SERPINB7</i>	-
19	1152656	rs892225	Yes	[SBNO2]	<i>GPX4</i>	-
<i>Sentinel SNPs identified in the GWAS of AOA</i>						
1	167420299	rs2056625	No	[CD247]	<i>CD247</i>	-
2	102892339	rs60227565	No	IL1RL2-[-IL18R1	-	<i>IL18RAP,IL1RL1,MFSD9</i>
2	102926362	rs12470864	No	IL1RL2-[-IL18R1	<i>IL18R1</i>	<i>IL18RAP</i>
2	242698640	rs34290285	No	[D2HGDH]	<i>PDCD1</i>	-
4	123353432	rs17454584	No	ADAD1-[-IL2	<i>KIAA1109</i>	-
5	35881376	rs11742240	No	IL7R-[-CAPSL	<i>IL7R</i>	-
5	131787137	rs6866614	No	[IRF1]	<i>AC116366.5,P4HA2,SLC22A5</i>	<i>IRF1,SLC22A4</i>
5	141518940	rs10699671	No	[NDFIP1]	<i>NDFIP1</i>	-
10	6093139	rs12722502	Yes	[IL2RA]	<i>IL2RA</i>	-

11	76293726	rs7936312	No	WNT11--[]-LRRC32	-	<i>LRRC32</i>
12	48186563	rs2544026	No	[HDAC7]	-	<i>HDAC7,RPAP3</i>
12	56449435	rs7302200	No	RPS26-[]-ERBB3	<i>ERBB3,GDF11,IKZF4,RAB5B,RPS26,SUOX</i>	<i>CDK2</i>
12	57489709	rs1059513	No	[STAT6]	<i>METTL21B,NAB2,STAT6</i>	-
13	40319954	rs28635831	Yes	[COG6]	-	<i>COG6</i>
13	100070457	rs4771332	Yes	MIR548AN-[]-TM9SF2	<i>CCR12P</i>	-
15	67441750	rs72743461	No	[SMAD3]	<i>AAGAB</i>	-

11 * The font pattern used for gene names is as follows. Italic: genes implicated by an eQTL but not by a non-synonymous variant. Italic and bold: genes
12 implicated by a non-synonymous variant but not an eQTL. Italic and underlined: genes implicated by both an eQTL and a non-synonymous variant.

13

14 eQTLGen Consortium – Author information

15 Mawussé Agbessi¹, Habibul Ahsan², Isabel Alves¹, Anand Andiappan³, Wibowo Arindrarto⁴, Philip Awadalla¹, Alexis Battle^{5,6}, Frank Beutner⁷, Marc
16 Jan Bonder^{8,9,10}, Dorret Boomsma¹¹, Mark Christiansen¹², Annique Claringbould⁸, Patrick Deelen^{8,13}, Tõnu Esko¹⁴, Marie-Julie Favé¹, Lude Franke⁸,
17 Timothy Frayling¹⁵, Sina A. Gharib^{16,12}, Gregory Gibson¹⁷, Bastiaan T. Heijmans⁴, Gibran Hemani¹⁸, Rick Jansen¹⁹, Mika Kähönen^{20,21}, Anette
18 Kalnapenkis¹⁴, Silva Kasela¹⁴, Johannes Kettunen²², Yungil Kim^{6,23}, Holger Kirsten²⁴, Peter Kovacs²⁵, Knut Krohn²⁶, Jaanika Kronberg-Guzman¹⁴,
19 Viktorija Kukushkina¹⁴, Zoltan Kutalik²⁷, Bernett Lee³, Terho Lehtimäki^{28,29}, Markus Loeffler²⁴, Urko M. Marigorta¹⁷, Hailang Mei⁴, Lili Milani¹⁴,
20 Grant W. Montgomery³⁰, Martina Müller-Nurasyid^{31,32,33}, Matthias Nauck³⁴, Michel Nivard¹¹, Brenda Penninx¹⁹, Markus Perola³⁵, Natalia
21 Pervjakova¹⁴, Brandon L. Pierce², Joseph Powell³⁶, Holger Prokisch^{37,38}, Bruce M. Psaty^{12,39,40}, Olli T. Raitakari^{41,42}, Samuli Ripatti⁴³, Olaf Rotzschke³,
22 Sina Rüeger²⁷, Ashis Saha⁶, Markus Scholz²⁴, Katharina Schramm^{31,32}, Ilkka Seppälä^{28,29}, Eline P. Slagboom⁴, Coen D.A. Stehouwer⁴⁴, Michael
23 Stumvoll⁴⁵, Patrick Sullivan⁴⁶, Peter-Bram 't Hoen⁴⁷, Alexander Teumer⁴⁸, Joachim Thiery⁴⁹, Lin Tong², Anke Tönjes⁴⁵, Jenny van Dongen¹¹, Maarten
24 van Iterson⁴, Joyce van Meurs⁵⁰, Jan H. Veldink⁵¹, Joost Verlouw⁵⁰, Peter M. Visscher³⁰, Uwe Völker⁵², Urmo Võsa^{8,14}, Harm-Jan Westra⁸, Cisca
25 Wijmenga⁸, Hanieh Yaghootkar¹⁵, Jian Yang^{30,53}, Biao Zeng¹⁷, Futao Zhang³⁰

26

27 Author list is ordered alphabetically.

- 28 1. Computational Biology, Ontario Institute for Cancer Research, Toronto, Canada
- 29 2. Department of Public Health Sciences, University of Chicago, Chicago, United States of America
- 30 3. Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore

- 31 4. Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
- 32 5. Department of Biomedical Engineering, Johns Hopkins University, Baltimore, United States of America
- 33 6. Department of Computer Science, Johns Hopkins University, Baltimore, United States of America
- 34 7. Heart Center Leipzig, Universität Leipzig, Leipzig, Germany
- 35 8. Department of Genetics, University Medical Centre Groningen, Groningen, The Netherlands
- 36 9. European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United Kingdom
- 37 10. Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany
- 38 11. Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- 39 12. Cardiovascular Health Research Unit, University of Washington, Seattle, United States of America
- 40 13. Genomics Coordination Center, University Medical Centre Groningen, Groningen, The Netherlands
- 41 14. Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu 51010, Estonia
- 42 15. Exeter Medical School, University of Exeter, Exeter, United Kingdom
- 43 16. Department of Medicine, University of Washington, Seattle, United States of America
- 44 17. School of Biological Sciences, Georgia Tech, Atlanta, United States of America
- 45 18. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
- 46 19. Department of Psychiatry and Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands
- 47 20. Department of Clinical Physiology, Tampere University, Tampere, Finland

- 48 21. Department of Clinical Physiology, Finnish Cardiovascular Research Center – Tampere, Faculty of Medicine and Life Sciences, University of
49 Tampere, Tampere, Finland
- 50 22. Centre for Life Course Health Research, University of Oulu, Oulu, Finland
- 51 23. Genetics and Genomic Science Department, Icahn School of Medicine at Mount Sinai, New York, United States of America
- 52 24. Institut für Medizinische Informatik, Statistik und Epidemiologie, LIFE – Leipzig Research Center for Civilization Diseases, Universität
53 Leipzig, Leipzig, Germany
- 54 25. IFB Adiposity Diseases, Universität Leipzig, Leipzig, Germany
- 55 26. Interdisciplinary Center for Clinical Research, Faculty of Medicine, Universität Leipzig, Leipzig, Germany
- 56 27. Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland
- 57 28. Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland
- 58 29. Department of Clinical Chemistry, Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Life Sciences, University of
59 Tampere, Tampere, Finland
- 60 30. Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia
- 61 31. Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
- 62 32. Department of Medicine I, University Hospital Munich, Ludwig Maximilian's University, München, Germany
- 63 33. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
- 64 34. Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany

- 65 35. National Institute for Health and Welfare, University of Helsinki, Helsinki, Finland
- 66 36. Garvan Institute of Medical Research, Garvan-Weizmann Centre for Cellular Genomics, Sydney, Australia
- 67 37. Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany
- 68 38. Institute of Human Genetics, Technical University Munich, Munich, Germany
- 69 39. Departments of Epidemiology, Medicine, and Health Services, University of Washington, Seattle, United States of America
- 70 40. Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States of America
- 71 41. Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland
- 72 42. Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland
- 73 43. Statistical and Translational Genetics, University of Helsinki, Helsinki, Finland
- 74 44. Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands
- 75 45. Department of Medicine, Universität Leipzig, Leipzig, Germany
- 76 46. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- 77 47. Center for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center
- 78 Nijmegen, Nijmegen, The Netherlands
- 79 48. Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
- 80 49. Institute for Laboratory Medicine, LIFE – Leipzig Research Center for Civilization Diseases, Universität Leipzig, Leipzig, Germany
- 81 50. Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands

- 82 51. Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands
- 83 52. Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany
- 84 53. Institute for Advanced Research, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China

85

86

87 BIOS Consortium (Biobank-based Integrative Omics Study)

88

89 **Management Team** Bastiaan T. Heijmans (chair)¹, Peter A.C. 't Hoen², Joyce van Meurs³, Aaron Isaacs⁴, Rick Jansen⁵, Lude Franke⁶.

90

91 **Cohort collection** Dorret I. Boomsma⁷, René Pool⁷, Jenny van Dongen⁷, Jouke J. Hottenga⁷ (Netherlands Twin Register); Marleen MJ van
92 Greevenbroek⁸, Coen D.A. Stehouwer⁸, Carla J.H. van der Kallen⁸, Casper G. Schalkwijk⁸ (Cohort study on Diabetes and Atherosclerosis Maastricht);
93 Cisca Wijmenga⁶, Lude Franke⁶, Sasha Zhernakova⁶, Ettje F. Tigchelaar⁶ (LifeLines Deep); P. Eline Slagboom¹, Marian Beekman¹, Joris Deelen¹,
94 Diana van Heemst⁹ (Leiden Longevity Study); Jan H. Veldink¹⁰, Leonard H. van den Berg¹⁰ (Prospective ALS Study Netherlands); Cornelia M. van
95 Duijn⁴, Bert A. Hofman¹¹, Aaron Isaacs⁴, André G. Uitterlinden³ (Rotterdam Study).

96

97 **Data Generation** Joyce van Meurs (Chair)³, P. Mila Jhamai³, Michael Verbiest³, H. Eka D. Suchiman¹, Marijn Verkerk³, Ruud van der Breggen¹,
98 Jeroen van Rooij³, Nico Lakenberg¹.

99

100 **Data management and computational infrastructure** Hailiang Mei (Chair)¹², Maarten van Iterson¹, Michiel van Galen², Jan Bot¹³, Dasha V.
101 Zhernakova⁶, Rick Jansen⁵, Peter van 't Hof¹², Patrick Deelen⁶, Irene Nooren¹³, Peter A.C. 't Hoen², Bastiaan T. Heijmans¹, Matthijs Moed¹.

102

103 **Data Analysis Group** Lude Franke (Co-Chair)⁶, Martijn Vermaat², Dasha V. Zhernakova⁶, René Luijk¹, Marc Jan Bonder⁶, Maarten van Iterson¹,

104 Patrick Deelen⁶, Freerk van Dijk¹⁴, Michiel van Galen², Wibowo Arindrarto¹², Szymon M. Kielbasa¹⁵, Morris A. Swertz¹⁴, Erik. W van Zwet¹⁵, Rick
105 Jansen⁵, Peter-Bram 't Hoen (Co-Chair)², Bastiaan T. Heijmans (Co-Chair)¹.

106

107 1. Molecular Epidemiology Section, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands

108 2. Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands

109 3. Department of Internal Medicine, ErasmusMC, Rotterdam, The Netherlands

110 4. Department of Genetic Epidemiology, ErasmusMC, Rotterdam, The Netherlands

111 5. Department of Psychiatry, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands

112 6. Department of Genetics, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

113 7. Department of Biological Psychology, VU University Amsterdam, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands

114 8. Department of Internal Medicine and School for Cardiovascular Diseases (CARIM), Maastricht University Medical Center, Maastricht, The
115 Netherlands

116 9. Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands

117 10. Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands

118 11. Department of Epidemiology, ErasmusMC, Rotterdam, The Netherlands

119 12. Sequence Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands

120 13. SURFsara, Amsterdam, the Netherlands

- 121 14. Genomics Coordination Center, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 122 15. Medical Statistics Section, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands